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1Foreword 
This National Poisons Information Service (NPIS) Annual Report 
for 2009/10 covers the fi fth year of the NPIS working as a 
UK-wide integrated network, which was introduced by the HPA 
in 2005. The Report reviews both the service support to the 
wider NHS in the last year and changes to the service over the 
fi ve year period.
The NPIS exists to support the wider NHS across the UK, 
to decrease the burden of the effects of poisoning on the 
population, by providing consistent information to support 
local carers in optimising the management of their poisoned 
patients, whether patients present to NHS Direct/NHS 24, 
primary care or the acute hospital services. 
The main purpose of the UK NPIS Annual Report is to provide 
statements of accountability and governance to the main 
joint funders of the service as well as to the HPA. These are 
the English Department of Health, the Scottish Assembly 
Government, the Welsh Assembly Government, the Northern 
Ireland Department of Health and Beaumont Hospital, Dublin, 
on behalf of the Republic of Ireland government.
This year’s review shows that both the NPIS and UKTIS 
(the UK Teratology Information Service) continue to provide 
a dynamic and responsive service to meet the constant new 
poisoning challenges presented by patients and their carers. 
The emergence of H1N1 pandemic fl u and new legal drugs of 
abuse such as cathinones, especially mephedrone, absorbed 
much NPIS and UKTIS time during the year. In addition, the 
service maintained its other expected routine work, particularly 
updating the 14,000 TOXBASE monographs necessary to 
ensure that up-to-date online advice is available to the service 
users. The service also developed advice for many new 
products, including liquid detergent products, and updated its 
advice to refl ect the constant reformulation of chemical and 
pharmaceutical products available.
UKTIS, a part of the NPIS, has had a major review, resulting 
in the appointment of its fi rst clinical lead and upgrading of 
its main database to record the outcomes of pregnancy in 
women exposed to drugs and chemicals.
NPIS staff have once again been very active in research, both 
nationally and internationally, producing data that underpin 
the advice offered by the service to UK clinicians. International 
legislation is mandating enhanced joint European working that 
is being led by the Health and Safety Executive in the UK.
Planned government-led changes to the status of the HPA and 
public health arrangements in England will inevitably mean 
change in the future commissioning arrangements for the NPIS 
and UKTIS, but the service as currently specifi ed is well placed 
to embrace these changes positively.
Elaine Lynch-Farmery
Centre for Radiation, Chemical and Environmental Hazards, 
Health Protection Agency
Simon Thomas
Chair, NPIS Clinical Standards Group 
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3Executive Summary
Background
Poisoning continues to be a substantial public health problem, 
accounting for over 140,000 NHS hospital admissions a year. 
The majority of people affected are cared for initially within 
hospital emergency departments and minor injuries units. 
Concerned patients and carers may also contact helplines 
(NHS Direct in England and Wales and NHS 24 in Scotland) for 
advice about possible poisoning and the need for attendance 
at an appropriate healthcare provider.
Since 2003 the Health Protection Agency has commissioned 
the National Poisons Information Service (NPIS) to support 
healthcare professionals within the UK in providing safe 
and effective diagnosis and management for people with 
suspected poisoning. The four units of the service are based 
in Birmingham, Cardiff, Edinburgh and Newcastle. The service 
has been expanded to involve additional on-call support 
from consultants with clinical toxicology training, working in 
London and York. The availability of expert advice also prevents 
unnecessary hospital admission when the risk of toxicity is low. 
The NPIS is a 24-hour-a-day service provided by scientifi cally 
qualifi ed specialists in poisons information (SPIs) and medically 
qualifi ed consultant clinical toxicologists.
Case data from telephone enquiries are entered on to 
a confi dential central secure database, UKPID, allowing 
coordinated data collection, better collaborative working and 
improved access to statistics related to poisoning enquiries. 
Data are also collected on usage of the NPIS online poisons 
database, TOXBASE. Examples of these data are provided in this 
report, and are used for public health surveillance purposes.
Activity
In 2009/10 the NPIS handled in excess of 578,000 enquiries by 
TOXBASE or telephone. Use of TOXBASE has been encouraged 
as a fi rst point of call for healthcare professionals. During 
the year there were 525,000 user sessions, a reduction of 
8% compared with the previous year. In order to support 
this activity a major task for the NPIS units is to maintain the 
database held on TOXBASE, the backbone of the service. 
Almost 4,900 TOXBASE entries were written or revised during 
this year.
There were 53,300 telephone enquiries made to the service 
in 2009/10, a slight fall of 6.5% compared with the previous 
year. The NPIS is often consulted about more serious cases of 
poisoning, and a signifi cant proportion of enquiries are referred 
to NPIS consultants for their expert opinion. In 2009/10, a total 
of 1,245 such high-level referrals were made, a 15% reduction 
over the previous year.
NHS acute hospitals account for the majority of NPIS activity, 
with over 60% (297,000) of the TOXBASE sessions and over 
30% (16,000) of telephone enquiries coming from this source. 
Enquiries from NHS Direct and NHS 24 accounted for 30% of 
TOXBASE sessions and 20% of telephone enquiries.
The NPIS includes the UK Teratology Information Service 
(UKTIS), which provides information on maternal and 
fetal effects of exposures to drugs and other chemicals 
in pregnancy. In 2009/10 there were approximately 
36,000 accesses to the pregnancy information on TOXBASE, 
and UKTIS answered around 4,200 pregnancy-related 
telephone enquiries, a similar fi gure to that for 2008/09. 
Areas of Interest in 2009/10
Household products are a very common source of enquiries 
to the NPIS. This year we have evaluated the effects of 
household cleaning products. These data illustrate the 
potential hazard of some types of product, particularly fabric 
cleaning products, in young children.
In 2009/10 there was a large increase in enquiries to the NPIS 
in relation to certain new drugs of misuse, especially synthetic 
cathinones. Monitoring NPIS enquiry data identifi ed the rapid 
increases in the use of these agents and these data helped to 
inform government policy on their control.
Pharmaceutical products remain the most frequent reason for 
enquiry to the NPIS. This year we have illustrated changes in 
enquiry patterns for antidepressants over the past fi ve years. 
We also highlight the issue of quinine, a product widely used 
in the UK for leg cramps which, in overdose, can cause serious 
toxicity, including permanent blindness.
4We also report on serious pesticide poisoning and trends in 
carbon monoxide enquiries. 
Finally, there has been an increase in the use of alcohol-based 
hand cleaners, both in NHS facilities and elsewhere, partly in 
response to concerns about MRSA and pandemic fl u. Enquiries 
to the NPIS about ingestion of these products have been 
increasing and these have provided useful information on the 
clinical features that result.
Governance and Quality Assurance
It is essential that the information provided by the NPIS is 
handled in a way which satisfi es governance procedures 
and is as accurate, up to date and relevant as possible. To 
achieve this, the NPIS holds regular national meetings for 
staff to promote professional development and to support 
consistent working across the four sites. There is systematic 
review of consultant level referrals to ensure that opportunities 
to improve the content of TOXBASE are taken and that the 
information provided reaches an agreed standard. User 
satisfaction surveys continue to indicate a very high level of 
overall satisfaction with the service provided, by TOXBASE, 
telephone enquiry services, and consultants.
Five Year Review
2009/10 marked the fi fth year of networked arrangements 
for the NPIS units, following establishment of a common 
NPIS rota in 2005. Over this period the NPIS has developed 
into a more cohesive national organisation, adopted new 
common operating procedures and standard practices, with 
coordinated on-call systems, call-switching and a single UK 
consultant clinical toxicologist rota. To support this, there has 
been an expansion of the numbers of NHS consultant clinical 
toxicologists working in the NPIS. New versions of the principal 
databases, TOXBASE and UKPID, have been developed. There 
have also been improvements within UKTIS. The NPIS has 
adopted unifi ed and coordinated quality assurance surveys of 
its activities.
The Future
The aim of the NPIS is to develop its services within the 
expected tight budgetary framework. Challenges over the 
next few years will include support for the London 2012 
Olympic Games, meeting the public health need to monitor 
and address new trends in poisoning and increasing our role 
in poisons prevention, while at the same time sustaining our 
current NPIS outputs, in particular TOXBASE and telephone 
response systems.
New European regulations affecting product labelling are also 
likely to increase demands on the NPIS. Requests for NPIS data 
from government agencies to support licensing decisions for 
pharmaceuticals, pesticides and chemicals are likely to increase 
and put additional pressure on existing scarce resources.
Research
Although NPIS staff are not funded to perform research as 
a core function, many staff are involved in research. This is 
usually funded by other parts of the NHS or by universities. This 
is an important function since it supports new developments 
in clinical care of poisoned patients and increases the evidence 
base for NPIS advice on poisons management. It also benefi ts 
the overall public health.
In the report we illustrate research performed by staff 
associated with the NPIS by highlighting work in a number of 
areas. These include paracetamol poisoning, the effects of 
co-proxamol, psychoactive drugs, heavy metals and pesticides, 
and drug exposure in pregnancy.
Wider NPIS Contributions 
NPIS staff make many contributions to academic and 
regulatory activities, nationally and internationally. The very 
wide extent of these is illustrated in appendices to the report.
51 Introduction
The National Poisons Information Service (NPIS) is a network 
of dedicated units which is commissioned by the Health 
Protection Agency (HPA). All these units are linked to clinical 
treatment facilities within teaching hospitals in the UK.
The NPIS has provided information by telephone since 
1963. The poisons information database, TOXBASE 
(www.toxbase.org), was introduced in 1982 and was 
transferred to the internet and adopted as the fi rst-line 
information source for healthcare professionals in the UK 
in 1999. Over the past ten years the NPIS has changed 
both its structure and functionality. Its focus remains on 
assisting colleagues in all parts of the NHS to manage cases 
of poisoning. The information and advice provided by the 
NPIS is based on the published literature, experience from 
NPIS telephone enquiry data and direct clinical experience 
of difference types of poisoning managed in NPIS-linked 
clinical departments.
Poisoning continues to be an important public health issue in 
the UK. It accounts for over 140,000 NHS hospital admissions 
in the UK each year (just under 1% of the total number), 
creating a signifi cant workload for health service staff, 
especially hospital emergency departments and minor injuries 
units. Many thousands of different types of agent are involved 
and the appropriate management of poisoning is therefore 
a major task for the NHS, especially when new or unfamiliar 
agents are involved.
There has been a small reduction in poisoning-related patient 
admissions to hospitals throughout the UK over the past 
decade. This may refl ect in part national strategies aimed at 
reducing suicide and self-harm. The patterns of drugs involved 
have also changed in line with new approaches to therapy. 
For example, newer antidepressants and antipsychotic drugs 
are increasingly involved. Withdrawal of more toxic agents, 
such as the analgesic co-proxamol, has reduced exposures 
to these agents. These hospital admission data, illustrated by 
NHS fi nished consultant episodes, do not refl ect the very many 
attendances to emergency departments of patients who do 
not require admission, nor the large numbers of enquiries 
through NHS patient helplines (NHS Direct in England and 
Wales and NHS 24 in Scotland).
A core responsibility of the NPIS is therefore to assist in the 
appropriate triage, referral, assessment and treatment of 
patients in all settings within the NHS. The majority of people 
dying from poisoning do so before healthcare assistance 
is summoned. Nevertheless there are still opportunities to 
improve care for those with more severe poisoning, thus 
reducing morbidity or mortality. At the same time NPIS advice 
reduces the need for unnecessary hospital attendance by 
those who have been exposed to substances of relatively 
low toxicity.
Over the past fi ve years there has been an expansion in the 
number of consultant staff available to assist colleagues 
in the management of more seriously unwell cases. Some 
consultants working within the NPIS are now based in acute 
hospitals geographically separate from the four main NPIS 
units. This expansion in the availability of expertise supports 
UK resilience. Since the NPIS also receives many enquiries 
about children it has formalised existing support from expert 
paediatricians, particularly to assist in the review of standard 
advice for the management of poisoning in children. 
Advice on the management of household exposures is a 
common source of NPIS enquiries. This year the NPIS 
has been involved in a specifi c project on the toxicity of 
household products.
The NPIS is funded primarily through ‘Government Grant in Aid’ 
from the UK health departments, but receives some contract 
income and research income for specifi c projects, notably in 
2009 the award of a new three-year project from the Health 
and Safety Executive concentrating on monitoring health 
effects of exposures to pesticides and biocides.
Information on NPIS activity in 2009/10 is given in this 
report. In addition, an overview of NPIS developments and 
contributions over the past fi ve years is provided.
62 NPIS Structure
The NPIS provides a 24-hour-a-day consultant-supported 
clinical toxicology on-call service that gives advice on the 
diagnosis and management of poisoning, including the 
clinical effects of exposures arising from chemical incidents 
and accidents. 
There are currently four NPIS ‘provider’ units (two in England 
and one each in Scotland and Wales). The service has 
24-hour consultant clinical toxicologist support provided 
by NHS consultant staff in all four NPIS units and colleagues 
in two other NHS hospitals (Guy’s and St Thomas’ NHS 
Foundation Trust and York Hospitals NHS Foundation Trust). 
NPIS consultant clinical staff also provide specialist clinical 
services to their local populations.
The primary source of information provided by the NPIS is 
its online database, TOXBASE (www.toxbase.org), which is 
available to all UK healthcare professionals who register for 
it. TOXBASE underwent a software update in 2008 and was 
moved to a new platform. The NPIS also provides a 24-hour 
telephone information service for healthcare professionals 
using a single national telephone number (0844 892 0111) 
when further advice or information is needed.
In Northern Ireland, the Regional Medicines and Poison 
Information Service in Belfast provides a daytime information 
service on poisons; healthcare professionals use the NPIS 
out-of-hours. The NPIS is also contracted to provide poisons 
NPIS clinical consultants
NPIS information scientists
TOXBASE
(www.toxbase.org)
Enquiries from professional colleagues 
(generally acute trust NHS staff/DH)
NHS Direct/NHS 24
Enquiries from
the public
if unresolved online then via the 
NPIS national telephone number 
clinical support required if highly complex 
if population, political or media implications
HPA CRCE Chilton
How poisons enquiries are answered
7information for users in the Republic of Ireland: TOXBASE 
is provided to major hospital emergency departments 
and to the National Poisons Information Centre in Dublin. 
Out-of-hours telephone support is provided by both NPIS 
specialists in poisons information (SPIs) and NPIS consultant 
clinical toxicologists.
NPIS activity is refl ected in TOXBASE usage and telephone 
enquiries. The increasing use now being made of TOXBASE, 
encouraged by NPIS promotional exercises, allows staff 
to perform more strategic work for the service, including 
production of TOXBASE monographs. When fi rst received, 
telephone enquiries are managed by specialists in poisons 
information who may have a scientifi c, nursing or pharmacy 
background. NPIS consultant clinical toxicologists are available 
for further advice as required. 
Information on the potential toxicity of drugs and chemicals 
in pregnancy is provided by the UK Teratology Information 
Service (UKTIS, formerly NTIS). This was established as part of 
NPIS Newcastle in 1995. Information on aspects of the toxicity 
of drugs and chemicals in pregnancy is increasingly being 
made available on TOXBASE, and the service follows pregnancy 
outcomes in potentially exposed pregnant women to improve 
knowledge in this challenging area.
In order to maintain a consistent approach, irrespective 
of the provider unit answering an enquiry, it is essential 
to have national mechanisms for addressing issues that 
affect the service. A key development over recent years has 
been the formalisation of such arrangements within a UK 
strategic framework.
Commissioning issues are dealt with by the HPA NPIS 
Commissioning Group, which meets quarterly (or more often if 
required). Clinical issues, including clinical governance matters, 
are discussed at the NPIS Clinical Standards Group, which also 
meets quarterly, usually on the same day as the HPA NPIS 
commissioning meetings. These meetings are attended 
by a representative of the commissioner, a senior clinician 
from each provider unit, and a senior specialist in poisons 
information. Invitations are also sent to representatives of 
the National Poisons Information Centre in Dublin. Operating 
procedures are updated frequently and made available to NPIS 
staff on TOXBASE.
To encourage a common and evidence-based approach to 
the clinical management of poisoning, all NPIS clinical and 
information staff are invited to attend continuing professional 
development (CPD) meetings, which deal with new data and 
important clinical issues. These occur three times a year and 
have now been taking place for four years. Each provider unit 
hosts the event in turn.
There are also regular meetings and teleconferences of the 
TOXBASE Editing Group and the UKPID User Group. These also 
have representation from each provider unit and discuss issues 
relating to TOXBASE and UKPID, the common NPIS call-logging 
software. The National Poisons Information Centre in Dublin 
and the Northern Ireland Regional Medicines and Poison 
Information Service also contribute to TOXBASE development.
All NPIS telephone enquiries are now recorded for governance 
purposes and data logged within a national database (UKPID). 
This allows data on cases to be analysed more readily and is 
used to inform clinical management of subsequent cases. 
It can also be used to support UK pharmaceutical licensing 
decisions by the Medicines and Healthcare products Regulatory 
Agency (MHRA), and for studying the epidemiology of 
poisoning as reported to the NPIS.
83 2009/10 in Focus
3.1 Overall Service Profi le
The total number of TOXBASE user sessions (defi ned as 
one logon to the TOXBASE site during which the user may 
access one or more products several times) was 524,986; 
a decrease of 8% on the number of sessions in 2008/09 
(Figure 3.1). This may in part be due to unusually high activity 
in 2008/09 following the introduction of new software. There 
has been a substantial increase in TOXBASE use over the last 
ten years. 
The number of user sessions includes 4016 educational 
sessions, an 11% increase on the 2008/09 fi gure. 
Sessions from all the NPIS units and from the Northern Ireland 
Regional Medicines and Poison Information Service have been 
excluded from further detailed analyses, as these units may 
access TOXBASE for training/educational purposes, to access 
operating procedures or for monograph-writing purposes 
(NPIS units only), as well as telephone answering.
Therefore a total of 479,951 sessions originating in England, 
Scotland, Wales and Northern Ireland have been analysed 
further in this report. Sessions originating overseas are 
presented elsewhere (Box 3.1).
There were 1,366,699 individual product accesses in 
2009/10; applying the same criteria as for session data, 
1,172,082 product accesses have been analysed further.
FIGURE 3.1  Telephone enquiries and TOXBASE sessions from 2000 to 2009/10 (data for 2000–2003 by 
calendar year; subsequent years by fi nancial year)
BOX 3.1 Non-UK and Subscription 
Users of the NPIS
The NPIS provides out-of-hours telephone support under 
contract to the Republic of Ireland. During 2009/10 
there were 2026 telephone enquiries routed to the NPIS 
national telephone service from this source. NPIS units 
also received 341 telephone enquiries from the Channel 
Islands and the Isle of Man (an increase of 1.5% on the 
2008/09 fi gure).
As well as the out-of-hours contract, the NPIS provides 
TOXBASE specifi cally tailored to medical professionals 
in the Republic of Ireland; in 2009/10 there were 
14,503 TOXBASE sessions made by 56 registered Irish 
users. The majority of Irish sessions originated in hospital 
emergency departments.
TOXBASE is provided under special agreements to users 
in 35 countries outside the British Isles; 13,203 TOXBASE 
sessions were made by these users, with those in Brazil 
(25%), Belgium (12%), Australia (9%), Hong Kong (9%) 
and Austria (8%) the most frequent users; the majority 
of sessions were made by poison centres (around 38%) 
and hospital departments (14%). The most common 
products accessed by users in the UK, the Republic 
of Ireland and overseas are compared in Table 3.4 
(see page 12). Although paracetamol and ibuprofen 
were the most commonly accessed pharmaceutical 
agents in all countries, the data suggest different 
patterns of exposure to some psychoactive drugs.
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9The total number of telephone enquiries received by the NPIS in 
2009/10 was 53,329 (excluding 4213 calls made to UKTIS) – this 
is a decrease of 6.5% from 2008/09 (Figure 3.1). The analyses 
presented in this report include only telephone enquiries to the 
NPIS which related to patients, of which there were 52,057.
Table 3.1 shows the number of poisons enquiries from UK 
countries and relates these to population. Table 3.2 shows 
the variation in TOXBASE use by strategic health authorities 
in England compared with use in Scotland, Wales and 
Northern Ireland.
TABLE 3.1  Origin of poisons enquiries to the NPIS in 2009/10 
Country
Telephone enquiries 
(involving patients) TOXBASE sessions Combined total
Number
Rate per 100,000 
population* Number
Rate per 100,000 
population* Number
Rate per 100,000 
population*
England 42,999 83.5 386,996 752.0 429,995 835.5
Scotland 2,156 41.7 52,791 1,021.4 54,947 1,063.1
Wales 3,892 130.2 29,197 976.5 33,089 1,106.6
Northern Ireland 643 36.2 10,967 617.9 11,610 654.1
* Based on 2008 estimates from www.statistics.gov.uk, accessed July 2010
TABLE 3.2  Regional distribution of TOXBASE sessions in 2009/10
Country Strategic health authority Number of TOXBASE sessions
TOXBASE sessions per 100,000 
population*
England East Midlands 33,093 747.1
East of England 40,949 716.2
London 46,594 607.6
North East 22,757 885.3
North West 59,858 870.8
South Central 34,212 842.8
South East Coast 21,185 491.6
South West 40,717 781.4
West Midlands 41,659 770.3
Yorkshire and The Humber 45,919 880.1
Scotland – 52,791 1,021.4
Wales – 29,197 976.5
Northern Ireland – 10,967 617.9
* Based on 2008 estimates from www.statistics.gov.uk, accessed July 2010
Figure 3.2 shows that hospital departments and NHS Direct/
NHS 24 users are responsible for the majority of TOXBASE 
sessions – 297,059 (62%) and 142,458 (30%), respectively. 
In contrast, telephone enquiries received were distributed 
more evenly across hospital, primary care and NHS Direct/
NHS 24 users – 16,719 (32%), 15,714 (30%) and 10,238 (20%), 
respectively. This is because GPs are more likely to call the NPIS 
than access TOXBASE.
The great majority of TOXBASE sessions from hospital users 
were from emergency departments (258,072 or 87%). 
10
The second largest group of hospital users were medicines 
information departments and pharmacies (25,975 or 9%). 
Of the telephone enquiries, 45% (23,276) were made by 
doctors and 41% (21,139) by nurses; these proportions are 
almost identical to those in previous years. The ages of 
patients who were the subject of telephone enquiries are 
shown in Figure 3.3; one-third of the telephone enquiries 
involved children under the age of fi ve years.
FIGURE 3.3  Age of patients reported in telephone enquiries 
to the NPIS in 2009/10
Females were involved in 55% of telephone enquiries. This 
is similar to that in previous years. Figure 3.4 shows the 
type of poisonings reported to the NPIS during telephone 
enquiries in 2009/10; the largest single category of telephone 
enquiries was accidental ingestions which occurred at home. 
The majority (88%) of enquiries related to ingestion, with 
4% to inhalation, and 8% to other routes. Exposures in the 
home accounted for 87% of enquiries, while 3% were in the 
workplace, 2% in hospital or medical facilities, and 8% in other 
locations, e.g. schools. 
The types of agents that were the subject of TOXBASE sessions 
and telephone enquiries are shown in Figure 3.5. For both 
datasets pharmaceuticals are the most common source of 
enquiries (69% and 64%, respectively) followed by household 
products (12% and 17%, respectively).
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type of user in 2009/10
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Table 3.3 shows the ten pharmaceutical agents that were 
the most frequent subject of telephone enquiries, with the 
corresponding TOXBASE accesses given in Table 3.4. It should 
be noted that the number of enquiries and accesses listed for 
paracetamol do not include those for compound analgesics 
(e.g. those containing both paracetamol and codeine), which 
are counted separately. The pattern of enquiries and accesses 
is similar to that of the previous two years, with analgesics and 
antidepressants predominating. The most common products 
accessed on TOXBASE by users in the UK, the Republic of 
Ireland and overseas are compared in Table 3.4.
Table 3.5 shows the household agents most frequently 
accessed during TOXBASE sessions in 2009/10; the most 
common were surfactants (26,812) and bleaches (16,854). 
The surfactant accesses include a range of different products 
containing surfactants as the active ingredient, e.g. non-
ionic, anionic and cationic surfactants. Aspects of this type of 
exposure are also discussed in Section 4.1.
FIGURE 3.5  Types of agents involved in telephone enquiries 
and that users accessed during TOXBASE sessions in 2009/10
BOX 3.2 TOXBASE Editing
With the increased use of TOXBASE by healthcare 
professionals as the fi rst, and often only, source of 
advice, it is essential that the information it contains is 
kept as up to date as possible. Because of the numbers 
of monographs involved, this is a very substantial 
workload, which is shared by all the NPIS units. TOXBASE 
entries that are new to the database and major updates 
are circulated to all the NPIS units for review before 
going ‘live’. The database is updated on a daily basis.
The HPA NPIS TOXBASE Editing Group includes 
representatives of clinical and information staff from 
all the NPIS units, together with representatives from 
related poisons centres, a public health physician 
and a scientist from the HPA Centre for Radiation, 
Chemical and Environmental Hazards. It meets 
approximately three times a year to agree policy for 
TOXBASE development, discuss the format of TOXBASE 
monographs, and agree and prioritise work programmes 
on the database content.
Areas of clinical controversy or uncertainty are discussed 
at regular meetings or teleconferences of the TOXBASE 
Editing Group or by the NPIS Directors at the quarterly 
NPIS Clinical Standards Group meetings. Monthly 
literature reviews are circulated as Current Awareness 
in Clinical Toxicology (see Section 3.5), to assist in 
updating TOXBASE.
The NPIS aims to review each of the approximately 
14,000 entries on TOXBASE at least every four years. 
Consistent with this aim, during 2009/10, 4897 entries 
were written or revised, an increase of 28% over the 
fi gure for 2008/09. 
Accidental 
    48%
Deliberate 27%
Drugs of misuse 2%
Therapeutic error 19% 
Other 4%
FIGURE 3.4  Types of poisonings as reported in telephone 
enquiries to the NPIS in 2009/10
Pharmaceuticals 
   64%
Other 1%Cosmetics 3%
Chemicals 15%  
Agrochemicals 1%
(including home use)  
Household 12%
Plants/fungi 4%
Telephone enquiries
Pharmaceuticals 
   69%
Other 2%Cosmetics 3%
Chemicals 5%
Agrochemicals 3%
(including home use)  
Household 17%
Plants/fungi 1%
TOXBASE sessions
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TABLE 3.5  Household agents: top TOXBASE accesses in 
2009/10
Agent Number of accesses
Surfactants plus detergents 
(e.g. washing powders, washing-up 
liquids and fabric cleaning liquid 
tablets)
26,812
Bleaches 16,854
Isopropanol (e.g. hand gels and 
screenwashes)
2,931
Anti-freeze and de-icers 2,504
Silica gel 2,408
Batteries 2,232
Petroleum distillates 2,008
White spirit (e.g. paints and 
varnishes) 1,633
Descalers 1,529
Cyanoacrylate (e.g. glues) 1,496
TABLE 3.3  Pharmaceutical agents: top telephone 
enquiries in 2009/10
Agent Number of enquiries
Paracetamol* 5,417
Ibuprofen 2,517
Co-codamol 1,339
Diazepam 1,164
Citalopram 1,140
Zopiclone 1,069
Fluoxetine 712
Salicylates† 688
Tramadol 642
Mirtazapine 556
* Excludes compound analgesics (eg those containing 
paracetamol and codeine)
† Includes aspirin
TABLE 3.4  Pharmaceutical agents: top TOXBASE accesses by UK, Republic of Ireland and overseas users in 2009/10
Rank
UK Republic of Ireland Overseas
Agent
Number of 
accesses 
(% of total) Agent
Number of 
accesses 
(% of total) Agent
Number of 
accesses 
(% of total)
1 Paracetamol* 71,652  (6.3%) Paracetamol* 1,810  (6.6%) Paracetamol* 615  (3.6%)
2 Ibuprofen 42,726  (3.7%) Ibuprofen 888  (3.2%) Ibuprofen 325  (1.9%)
3 Codeine† 25,573  (2.2%) Codeine† 731  (2.7%) Quetiapine 273  (1.6%)
4 Salicylates‡ 25,452  (2.2%) Diazepam 690  (2.5%) Carbamazepine 268  (1.6%)
5 Citalopram 22,483  (2%) Salicylates‡ 619  (2.3%) Amitriptyline 263  (1.5%)
6 Diazepam 20,646  (1.8%) Zopiclone 604  (2.2%) Salicylates‡ 242  (1.4%)
7 Fluoxetine 18,227  (1.6%) Escitalopram 520  (1.9%) Sertraline 212  (1.2%)
8 Zopiclone 17,092  (1.5%) Venlafaxine 509  (1.9%) Venlafaxine 212  (1.2%)
9 Tramadol 12,435  (1%) Alprazolam 440  (1.6%) Diazepam 208  (1.2%)
10 Amitriptyline 11,837  (1%) Quetiapine 374  (1.4%) Fluoxetine 208  (1.2%)
* Excludes compound analgesics containing paracetamol and codeine
† Includes all codeine-containing products
‡ Includes aspirin
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3.2 Consultant Referrals
Background
Since May 2005, the NPIS has operated a national consultant 
clinical toxicology on-call rota. Currently eleven consultant 
clinical toxicologists from the four units (Birmingham, Cardiff, 
Edinburgh and Newcastle) participate, as well as three 
consultants from hospitals in London and York, who also 
contribute to out-of-hours cover (18.00 to 09.00, Monday to 
Thursday, weekends and public holidays) for the UK and the 
Republic of Ireland. All staff on the rota are involved in the care 
for poisoned patients in their own local NHS poisons treatment 
facilities. A nationally agreed protocol is used to determine 
when specialists in poisons information (SPIs) should refer 
enquiries to a consultant. The national rota is managed from 
NPIS Edinburgh.
For daytime cover, units continue to make local arrangements 
and may be supported by consultants, academic clinical 
staff and specialist registrars (SpRs) who are not on the 
UK NPIS consultant toxicologist rota, but all enquiries are 
answered under the supervision of NPIS consultants. NPIS 
Edinburgh also provides consultant support for Northern 
Ireland enquiries during the working week. Units provide 
cross-cover in emergencies and occasionally, in a planned 
manner, support colleagues in special circumstances during 
the working week.
For telephone enquiries details of the original call are 
available on the UKPID central server for audit and checking, 
and the call reference number is sent to the relevant 
consultant for audit purposes. In addition, consultants keep 
contemporaneous local records of advice given, which are 
passed to the NPIS unit that took the original call for addition 
to the call record. 
For the purposes of collating and auditing consultant referrals, 
NPIS Cardiff provides a monthly spreadsheet of enquiries that 
were referred to a consultant. Data on day and month, source 
and agents are given below.
Referrals
There were 1245 referrals made to the consultant rotas 
(daytime and out-of-hours) in 2009/10, a 15% decrease on 
2008/09. Figure 3.6 shows referrals by month since April 2006. 
The distribution by day of the week is shown in Figure 3.7, 
with fewer consultant referrals at the weekend. The 
average number of referrals per day was 3.4 (the range is 
0–13 referrals). Table 3.6 shows consultant referrals by country.
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FIGURE 3.6  Monthly NPIS consultant referrals (including out-of-hours and workday referrals) since April 2006
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The vast majority of consultant referrals came from hospitals 
(1123 referrals or 90.2%), with GPs (70; 5.6%), NHS Direct/
NHS 24 (20; 1.6%) and others (31; 2.5%) making much smaller 
contributions. Hospital referrals by department are shown 
in Table 3.7. There was a slight increase in the proportion 
of referrals from units other than emergency departments, 
compared with previous years.
TABLE 3.7  NPIS consultant referrals from hospital by 
department in 2009/10 
(where confi rmed, 1092 referrals)
Source
Number of 
referrals
% of 
referrals
Emergency departments 430 39.4
HDU/ITU 232 21.2
Medical 105 9.6
Paediatric 100 9.2
Admissions/short stay/
assessment
100 9.2
Pharmacy/MI 328 2.6
Surgery 15 1.4
Psychiatry 5 0.4
Others 77 7.0
Table 3.8 shows the most common types of products involved 
in referrals to consultants. These were paracetamol-containing 
products, cardiac drugs, substances of abuse, benzodiazepines 
and toxic alcohols or glycols (e.g. ethylene glycol/methanol/
anti-freeze). In 75 referrals the product taken (if any) was 
unknown and help with diagnosis was required. Alcohol was 
involved in 92 consultant referrals.
FIGURE 3.7  NPIS consultant referrals in 2009/10 by day of 
the week
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TABLE 3.6  NPIS consultant referrals by country in 2009/10, with 2008/09 for comparison
Country Number of referrals Rate per 100,000 population* % 2009/10 % 2008/09
England 911 1.8 73.2 72.4
Scotland 197 3.8 15.8 19.0
Wales 86 2.9 6.9 5.9
Northern Ireland 20 1.1 1.6 1.0
Republic of Ireland 22 – 1.8 1.3
Other 9 – 0.7 0.5
Total 1245
* Based on 2008 estimates from www.statistics.gov.uk, accessed June 2010
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TABLE 3.8  Agents commonly involved in NPIS 
consultant referrals in 2009/10
Product Number of referrals
Paracetamol 202
Digoxin 47
Iron 44
Ibuprofen 39
Aspirin 36
Co-codamol 34
Ethylene glycol 31
Diazepam 27
Amitriptyline 23
Amlodipine 21
Feedback into NPIS services
Analysis of the consultant referrals is used to improve the 
services offered by the NPIS. This includes additions and 
changes to TOXBASE entries that refl ect user needs. Issues 
highlighted by such calls, especially those that are diffi cult or 
complex, are discussed further amongst NPIS staff by email 
or telephone, and diffi cult enquiries may be examined in 
more detail at one of the NPIS CPD meetings. This year CPD 
topics have included antidotes, recreational drug abuse and 
occupational exposures.
Conclusions
The NPIS national out-of-hours on-call consultant rota 
continues to work well. Frequent contact by email and 
telephone, together with regular educational meetings, helps 
to ensure consistency of advice. Information gleaned from 
analysis of the enquiries has assisted in identifying toxicological 
and methodological problems, improving the clarity of 
TOXBASE entries and informing the need for research in a 
number of areas. 
3.3 UKTIS
The UK Teratology Information Service (UKTIS) was established 
as part of NPIS Newcastle in 1995. It provides a national 
service on all aspects of the toxicity of drugs and chemicals in 
pregnancy. Information is provided to healthcare professionals 
by a telephone information service and also online through 
TOXBASE, which holds pregnancy summaries on maternal 
exposures to various drugs and chemicals, developed by 
UKTIS staff. To date, there are approximately 500 pregnancy 
monographs, 300 of which are available through TOXBASE. 
UKTIS also provides advice on drug and chemical exposure 
during pregnancy on request to offi cial organisations such as 
the Health Protection Agency, the Medicines and Healthcare 
products Regulatory Agency, the Commission for Human 
Medicines, the European Medicines Agency, the British National 
Formulary and the Neonatal Formulary.
UKTIS is a founder member of the European Network of 
Teratology Services (ENTIS) and works with the Organisation 
of Teratology Information Specialists (OTIS) in the USA and 
Canada. Together with ENTIS and OTIS, UKTIS collaborates and 
shares data, to try and prevent congenital malformations.
A further key role of UKTIS is to collect pregnancy outcome 
data from women who have been exposed to drugs and 
chemicals in pregnancy. These data contribute to provision of 
an individual risk assessment for a pregnant women exposed 
to drugs and chemicals, and preconception advice for men 
and women concerning drug and chemical exposures. 
Number and source of telephone enquiries
During 2009/10 UKTIS received 4213 pregnancy-related 
telephone enquiries, a decrease of less than 1% on the fi gure 
for 2008/09. The distribution of telephone enquiries taken 
by UKTIS in England, Scotland, Wales and Northern Ireland 
is shown in Table 3.9. In addition, UKTIS took 61 calls from 
outside the UK, the majority from the Republic of Ireland. 
A regional breakdown of calls taken in England is shown in 
Table 3.10. 
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TABLE 3.9  Distribution of telephone enquiries to UKTIS 
in 2009/10
Country
Number 
of 
enquiries
% of 
enquiries
Enquiries 
per million 
population*
England 3620 86 70.8
Scotland 270 6.4 52.5
Wales 208 4.9 69.9
Northern Ireland 54 1.3 30.7
Outside the UK, 
including the 
Republic of Ireland
61 1.4 N/A
Total 4213 100
* Based on 2008 estimates from www.statistics.gov.uk
TABLE 3.10  Regional distribution in England of 
telephone enquiries to UKTIS in 2009/10
UKMI region
Number of 
enquiries
% of 
enquiries
East Anglia 147 4
London – North Thames 579 16
London – South Thames 428 12
North East 441 12.2
North West 418 11.6
South Coast (Wessex) 250 7
South West 336 9.3
Trent 299 8.3
West Midlands 340 9.4
Yorkshire 367 10.2
Total 3605 100
The most frequent enquiry to UKTIS in 2009/10 was for patient 
information regarding zanamivir, the antiviral of choice in the 
UK for the prophylaxis and treatment of A/H1N1v infl uenza 
in pregnancy. UKTIS participated in the HPA emergency 
pandemic response plan by providing advice on swine fl u 
FIGURE 3.8  Top agents involved in telephone enquiries to UKTIS in the last four years, 2006/07 to 2009/10
infection and/or treatment in pregnancy and collecting 
epidemiological data during the early stages of the fi rst wave 
of the 2009 pandemic. The second and third most frequent 
enquiries in 2009/10 related to the use of the antidepressants 
citalopram and fl uoxetine (Figure 3.8). 
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FIGURE 3.9  Telephone enquiries and TOXBASE sessions from 2006/07 to 2009/10
TABLE 3.11  Updated pregnancy-related monographs added to TOXBASE in 2009/10
Aciclovir
Adalimumab
Ampicillin
Anthelmintics
Atenolol
Azithromycin 
Baclofen
Beta interferon
Bisoprolol
Celiprolol
Cholestyramine
Ciprofl oxacin 
Clozapine 
Doxycycline
Erythromycin 
Essential oils
Etanercept
Haloperidol
H1N1 infl uenza vaccine
Intrahepatic cholestasis 
of pregnancy
Infl iximab
Infl uenza vaccine 
Irbesartan 
Labetalol
Lithium
Losartan
Macrolides 
Mebendazole
Metoprolol
Mifepristone
Mirtazapine
Montelukast nadolol
Nausea and vomiting 
Nebivolol
Nitrofurantoin
Olanzapine 
Oseltamivir
Oxprenolol
Podophyllin
Propranolol
Quetiapine 
Quinolones 
Ribavirin
Risperidone 
Rituximab
Sotalol
Swine fl u
Thalidomide
Timolol
Ursodeoxycholic acid
Yellow fever vaccine
Zanamivir 
Zolpidem
Pregnancy summaries 
To assist with enquiry answering, summary information has 
been written for a number of drugs and chemicals. The 
pregnancy summaries (monographs) hosted by the TOXBASE 
website had approximately 36,000 accesses during 2009/10, 
a slight increase compared with 2008/09 (Figure 3.9). These 
fi gures are in keeping with the trend of the past few years, 
which has shown a gradual decrease in telephone enquiries 
accompanied by a steady increase in TOXBASE use.
In 2009/10, 54 new and updated pregnancy monographs 
were added to TOXBASE (Table 3.11). Monographs produced 
this year included information regarding maternal exposure 
to immunosuppressants, the beta adrenoceptor blocking 
drugs, infl uenza A/H1N1v vaccine and the anitivirals zanamivir 
and oseltamivir.  
The most frequently accessed documents were those relating 
to swine fl u in pregnancy, with 4194 hits for the swine 
fl u in pregnancy and antiviral (oseltamivir and zanamivir) 
documents. The next most accessed documents related to 
antibiotics (1815 hits) and nausea and vomiting (1472 hits) in 
pregnancy. The top 20 most accessed TOXBASE monographs 
for 2009/10 are listed in Table 3.12. 
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TABLE 3.12  Top 20 most accessed pregnancy summaries 
on TOXBASE in 2009/10
Pregnancy monograph
Number of 
accesses
Swine fl u 1927
Antibiotics 1815
Nausea and vomiting 1472
Oseltamivir 1348
Zanamivir 919
Malaria prophylaxis 859
Citalopram 846
Codeine 835
Amitriptyline 706
Chlorphenamine 624
Corticosteroids 611
Antidepressants and neonatal withdrawal 600
Migraine 550
Gabapentin 538
Cetirizine 517
Atenolol 497
Trimethoprim 488
Doxycycline 472
Metronidazole 472
Antispasmodics 452
UKTIS summary sections of updated or new pregnancy 
monographs continue to be hosted by the National electronic 
Library for Medicines website (www.nelm.nhs.uk). These 
summaries are freely accessible over the internet with 
instructions to link to TOXBASE for access to the complete 
monographs. Alerts are sent to registered NHS users by email 
when any new or updated pregnancy summary is published. 
Nature of telephone enquiries
Of the 4213 enquiries to UKTIS during 2009/10, 3430 (81%) 
concerned maternal pregnancy exposures. The majority 
of calls (43%) were regarding pregnant women who had 
already been exposed to a drug or chemical, whilst 27% were 
regarding preprescription enquiries. Around 14% of enquiries 
were made regarding general information on drug and 
chemical exposures in pregnancy. Information for women who 
were planning pregnancy, but not yet pregnant, made up 10% 
of all the enquiries to UKTIS in this fi nancial year (Figure 3.10). 
Hospital pharmacists (41%) remain the most frequent type of 
caller, followed by GPs (25%), consultants (7%) and community 
pharmacists (6%) (Figure 3.11). Therapeutic use of medicines 
during pregnancy remains the largest category about which 
enquiries are made (90%) (Table 3.13).
TABLE 3.13  Telephone enquiries to UKTIS by type of 
exposure in 2009/10
Type of exposure
Number of 
enquiries
% of 
enquiries
Therapeutic 3786 90
Drug overdose 116 2.7
Poisoning 142 3.4
Substance abuse 23 0.5
Complementary medicines 11 0.3
Occupational 45 1.1
Environmental 38 0.9
Miscellaneous 52 1.2
Total 4213 100
FIGURE 3.10  Telephone enquiries to UKTIS by category of 
exposure in 2009/10
Pregnancy 
    43%
Retrospective 2%
General
information 14% 
Lactation 1%
Paternal 3%
Preconception 10%
Preprescription 27%
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FIGURE 3.11  Telephone enquiries to UKTIS by type of caller 
in 2009/10
Pregnancy follow-up and outcomes
Limited data exist on the potential fetotoxicity of drug and 
chemical exposures in pregnancy. UKTIS therefore attempts 
to obtain pregnancy outcome details for all enquiries where 
suffi cient patient identifi cation is provided. In the fi nancial 
year 2009/10, UKTIS attempted to follow up 2223 (53%) 
of enquiries made to the service. A large number of these 
pregnancies are still ongoing, but we have already received 
the outcome for 462 pregnancies. A further 116 women 
were lost to follow-up, 13 were found to be not pregnant and 
61 were ultimately not exposed to the drug about which their 
healthcare professional had enquired.
Teaching and training 
UKTIS has continued to provide training in teratology-related 
subjects to undergraduate and postgraduate students at a 
national level. Training was provided externally for the Drug 
and Safety Research Unit in Southampton and also for the 
Royal College of Obstetricians and Gynaecologists during 
2009/10. UKTIS also hosted a ‘Medication in Pregnancy’ 
workshop at the annual UKMi conference held in Edinburgh 
in 2009. 
In 2009/10, eight new staff members within NPIS Newcastle 
and UKTIS were trained to answer teratology enquiries. 
Training material for teaching purposes has continuously been 
updated throughout the year to refl ect new published data 
and evidence. A full day of in-house critical appraisal training 
was also provided by UKTIS for a number of UKTIS and NPIS 
Newcastle specialists.
UKTIS pregnancy outcome data from routine 
surveillance activity
UKTIS has been proactive in producing abstracts for various 
regional, national and international conferences. UKTIS data 
on cannabis, hepatitis A and B vaccines, trichloroethylene, 
aspirin overdose and A/H1N1v infl uenza were presented at 
conferences throughout 2009/10. Abstracts have already been 
prepared and accepted for meetings in 20010/11 to include 
data on maternal exposure to diazepam overdose, ibuprofen 
overdose in the third trimester, and mifepristone in pregnancy. 
Service developments in 2009/10
Appointment of new head of teratology 
Dr Laura Yates was successfully appointed as the new head of 
UKTIS and Consultant in Clinical Genetics in Autumn 2009. 
Software development
The development of new software suitable for logging 
pregnancy enquiries and to house legacy outcome data 
continued throughout 2009/10. This new state-of-the-art 
software will allow for more effi cient logging, checking 
and follow-up of pregnancy enquiries, and will enable the 
generation of automated reports on all exposures, improving 
UKTIS surveillance of potential teratogens. The new database 
went live in the latter half of 2010. To date, all UKTIS legacy 
data have been successfully migrated into the new system 
and this part of the system is now up and running and 
working successfully.
0
500
1000
1500
2000
Nu
rse
Mi
dw
ife
Ho
sp
ita
l p
ha
rm
ac
ist
Ph
arm
ac
ist
: o
the
r
Ho
sp
ita
l d
oc
tor GP
NH
S D
ire
ct
Ot
he
r
Enquirer profession
N
u
m
b
er
 o
f 
te
le
p
h
o
n
e 
en
q
u
ir
ie
s 
20
UKTIS website
This year also saw the launch of the UKTIS website. This aims 
to promote the service, provide contact details, and to provide 
access for healthcare professionals to reporting forms for 
both routine enquiries and for UKTIS studies (Figure 3.12). 
The website has been an invaluable tool to advertise the 
NIHR A/H1N1v Infl uenza in Pregnancy Study and to provide 
healthcare professionals and participants with forms and 
information about the study. To date, www.UKTIS.org has 
received just over 83,000 hits.
FIGURE 3.12  UKTIS website home page during 2009/10
3.4 Product Data Centre
Many accidental and deliberate poisonings occur from 
exposure to consumer products. In order for the NPIS to 
provide accurate advice on the treatment and management 
of such patients, reliable information on the composition 
of consumer products is necessary. Manufacturers’ product 
datasheets (‘Material Safety Data Sheets’, MSDS) also provide 
information for updating TOXBASE, enabling end-users to 
obtain specifi c advice on many common products.
NPIS Birmingham has the responsibility of providing product 
data on pesticides and herbicides to all the NPIS units and 
liaises with manufacturers to ensure that the data held are 
comprehensive and up-to-date. In 2009/10, 6506 MSDS were 
added to the NPIS Product Data Centre which now holds 
56,632 MSDS. The database is indexed by product name, 
manufacturer, date of MSDS, and the accession date for the 
MSDS to the database.
In practice, the most common search undertaken by NPIS 
staff of the Product Data Centre is by product name (full or 
partial name) and/or by manufacturer, which is the information 
usually available at the time of the NPIS enquiry. The date of 
the MSDS can differentiate between information on updated 
formulations. Where these fi elds are insuffi cient, the database 
is also fully text searchable, which enables searches to be made 
on any other criteria, e.g. active ingredients or use.
NPIS Birmingham has developed a database to support the 
Product Data Centre. This second database holds contact 
details for more than 2200 companies and assists in the 
tracking of correspondence with companies. It also includes 
data on the current marketing status of products such 
as pesticides.
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3.5 Current Awareness
To ensure that NPIS staff are equipped to answer enquiries 
on all aspects of human toxicology and that TOXBASE is kept 
up-to-date, access to current scientifi c literature is essential. 
With the assistance of the other NPIS units, NPIS Birmingham 
produces Current Awareness in Clinical Toxicology each month. 
Each issue lists some 300 citations, with around 12–16 key 
papers highlighted because of their importance to the clinical 
management of poisoning. In the digital version, 84% of the 
citations have abstracts. Citations are selected using searches 
specially developed for the purpose run against Medline, 
Embase and Science Direct. In addition, the tables of contents 
of key journals are scanned for suitable papers on publication.
Current Awareness is distributed electronically or in hard copy 
to all the NPIS units and can be used to produce citations for 
scientifi c papers employing any reference style. In addition, 
the American Academy of Clinical Toxicology (AACT), 
the European Association of Poisons Centres and Clinical 
Toxicologists (EAPCCT) and the Asia Pacifi c Association of 
Medical Toxicology (APAMT) distribute Current Awareness to 
their members worldwide.
All citations in Current Awareness are added to a literature 
database, which currently contains 71,000 references. The 
database is fully searchable using keywords, authors, journals 
and text words. 
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This chapter includes a selection of activities conducted by the 
NPIS and reports on poisons that have specifi c aspects that 
may be of interest.
4.1 Household Products
The NPIS receives many enquiries related to possible exposures 
to household products. Recently, for a prospective study, 
the NPIS units collected 5939 consecutive enquiries relating 
to 6086 household cleaning products received from UK 
physicians and other healthcare workers over a 14-month 
period. Where possible, to determine outcome, each enquiry 
was followed up by telephone within four hours to ensure that 
the maximum data were obtained.
The majority of enquiries (65%) concerned children of 
fi ve years of age or less (Figure 4.1) and were received 
predominantly from hospitals (32%), general practitioners 
(30%) and NHS Direct/NHS 24 (28%). 
The vast majority of exposures occurred at home (98%), 
with less than 1% occurring at work. Most exposures were 
accidental (94%). Exposure was acute (<2 hours) in 99% of 
cases; staggered (2 – 24 hours) in 0.2% of cases, 0.4% of cases 
were sub-acute (24 hours – <1 month), and 0.3% were chronic 
(>1 month). 
Table 4.1 shows the top 20 common products to which patients 
were exposed; more details on exposures to fabric cleaning 
liquid tablets are provided below. Intentional exposures were 
more likely to involve bleaches, multipurpose cleaners and 
disinfectant/antiseptic/sanitiser liquids (Table 4.2).
Exposure to household products occurred mainly as a result 
of ingestion (76%), with eye contact (8%), inhalation (7%) and 
skin contact (3%) being less common; 5% of enquiries involved 
multiple routes of exposure.
TABLE 4.1  Type of product involved in telephone 
enquiries related to household products in 2009/10
Product
Number of 
enquiries
Fabric cleaning liquid tablets 647
Bleach 473
Multipurpose cleaner 408
Descaler 397
Disinfectant/antiseptic/sanitiser liquid 270
Plug ins liquid 206
Dishwasher tablet 201
Toilet cleaner/freshener liquid 156
Washing up liquid 130
Prewash stain remover 116
Rinse aid 112
Biocidal hand cleanser (domestic use) 104
Fabric cleaning powder tablet 102
Floor cleaner 101
Bathroom/bath cleaner 100
Toilet cleaner/freshener solid/powder 99
Fabric cleaning powder 95
Fabric cleaning liquid 94
Toilet rim block 80
Insect control powder (domestic use) 79
4 Areas of Interest in 2009/10
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FIGURE 4.1  Age range of patients involved in telephone 
enquiries related to household products in 2009/10
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TABLE 4.2  Intentional exposures involved in telephone 
enquiries related to household products in 2009/10
Product
Number of 
enquiries
Bleach 88
Multipurpose cleaner 31
Disinfectant/antiseptic/sanitiser liquid 28
Toilet cleaner/freshener liquid 22
Bathroom/bath cleaner 11
Floor cleaner 11
Screenwash 11
Window/glass cleaner liquid 10
Fabric conditioner liquid 6
Washing up liquid 6
Descaler 5
Kitchen cleaner 5
Common features that developed following exposure to a 
household product(s), and which were present at the time of 
the enquiry, are shown in Table 4.3. In 5840 of 5939 enquiries 
the poisoning severity score* was known at the time of the 
enquiry. The majority of patients (70%) were asymptomatic, 
but 1635 patients developed minor, 75 moderate and 
ten patients serious features, two of whom died (see below).
Follow-up and outcome
Of the 5939 enquiries, 3403 were not or could not be 
followed up. These are shown by source of enquiry in 
Figure 4.2. Follow-up of the enquiries received from 
NHS Direct/NHS 24, GP out-of-hours services, walk-in centres 
and ambulance services (some 75% of all enquiries that 
could not be followed up) was not usually attempted, as the 
enquirers do not routinely collect follow-up data.
TABLE 4.3  Features present at the time of the telephone 
enquiries related to household products in 2009/10
Features
Number of 
enquiries
Skin contact
Chemical burn/ulcer 47
Rash 21
Skin reaction 16
Skin irritation 16
Bullous eruption 13
Paraesthesiae 9
Eye contact
Eye pain 137
Eye irritation 106
Conjunctivitis 84
Increased lacrimation 11
Abnormal vision 7
Chemical burn to the eye 7
Corneal ulceration/abrasion/opacity 7
Inhalation
Dyspnoea/bronchospasm 75
Cough 54
Chest pain 51
Pharyngitis/laryngitis 48
Nausea/vomiting 28
Headache 24
Ingestion
Vomiting 333
Pharyngitis/laryngitis/throat irritation/
stomatitis 
132
Nausea 113
Abdominal pain 112
Cough 74
Diarrhoea 42
Drowsiness and coma 35
Haematemesis 12
*  Persson HE, Sjoberg GK, Haines JA, Pronczuk de Garbino J. Poisoning 
severity score. Grading of acute poisoning. J Toxicol Clin Toxicol 1998; 36: 
205–13.
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FIGURE 4.2  Source of telephone enquiries related to 
household products in 2009/10, where follow-up data are 
not available
Follow-up data were available in 2536 cases, of which the 
majority (70%) are known to have made a full recovery. 
The outcome is unknown in 26% of cases where follow-up 
was attempted but not obtained due to the patient self-
discharging, the enquirer going off duty, or the patient being 
transferred to a different hospital/ward. Eighty-one patients 
developed complications of exposure and two patients, both 
adults, died, probably due to self-harm.
Fabric cleaning liquid tablets
Historically laundry detergents were available as powders or 
as liquids intended to be poured into a washing machine or 
dispenser. More recently, washing sachets, sometimes referred 
to as ‘liquitabs’, have become available. These sachets contain 
a liquid washing agent within a fl exible container and are 
intended to be placed directly into the drum of a washing 
machine. Upon contact with water the fl exible sachet breaks 
down releasing the contents.
Whilst these sachets are mechanically strong when dry, they 
can release their contents prematurely when they come into 
contact with moisture – for example, from water or a moist 
hand. Their contents are irritant and concern has been raised 
about their ability to cause local damage, especially damage 
to the eyes. In addition, some cases of children exposed 
to the contents of these sachets had been reported to the 
NPIS as having developed central nervous system depression 
unexpectedly. In total, 3979 TOXBASE accesses were made 
during 2009/10. This is an increase over the previous year’s 
total of 3164, and more than double the number of accesses 
for these products fi ve years ago.
In the prospective study of household cleaning product 
enquiries mentioned above, fabric cleaning liquid tablets were 
the most common product to which patients were exposed 
(647 enquiries). These exposures occurred most commonly 
as a result of ingestion (80%), with eye contact (10%) and skin 
contact (1%) being less frequent; 9% of enquiries involved 
multiple routes of exposure. The majority of enquiries (96%) 
concerned children of fi ve years of age or less. 
The eye was involved in 102 patients (106 enquiries); eye 
contact was the sole route of exposure in 60 of these patients 
and 92% were children aged fi ve years or less. Features that 
developed following ocular exposure were conjunctivitis 
(34 cases), which was associated with eye pain in eight cases; 
eye irritation (16 cases); eye pain (21 cases); increased 
lacrimation (four cases); corneal ulceration (three cases), 
which was still present in one patient nine days after exposure; 
and blurred vision (two cases). In 28 cases no features were 
recorded. We attempted to follow up all these enquiries and to 
the best of our knowledge all ocular damage resolved.
Because of concerns about the ability to cause serious 
eye injury, and because of reports of central nervous 
system depression, a customised form and warning was 
placed on TOXBASE and users were asked to report cases 
electronically. During the year, 28 forms were returned. Of 
these, 27 concerned children aged fi ve years or less; 18 cases 
involved ingestion, 12 eye exposure and three skin exposure. 
Of the 18 forms involving ingestion, eight reported features of 
central nervous system depression (with signs of sedation).
Exposure to the contents of these sachets is a matter of 
concern due to their potential to cause eye damage and 
because of the reports of central nervous system depression 
following ingestion. Greater consumer awareness is required to 
reduce injuries of this kind. Parents also have a vital role to play 
in ensuring that these products are stored safely at all times. 
NHS Direct/NHS 24 
     48%
GP out-of-hours      
 services 18%
Hospitals  
13%
Ambulance 
services 8%    
Other 5%Walk-in centres 1%
GPs 7%
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4.2 Drugs of Misuse
In previous years the NPIS has provided information about 
telephone enquiries and accesses to TOXBASE relating to 
selected drugs of misuse. This section provides a brief update 
on trends in activity. 
The major change in NPIS workload during 2009/10 has been 
the substantial increase in the numbers of telephone enquiries 
and TOXBASE accesses relating to cathinones, especially 
mephedrone (Figures 4.3 and 4.4). This drug was rarely 
involved in NPIS enquiries prior to this year, but during 2009/10 
was the most common recreational drug involved in NPIS 
FIGURE 4.3  TOXBASE accesses relating to selected cathinones made each month in 2009/10
FIGURE 4.4  Telephone enquiries relating to selected cathinones made each month in 2009/10
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telephone enquiries and the third most commonly involved 
in TOXBASE accesses (Figure 4.5). Enquiries relating to other 
cathinones, including methylenedioxypyrovalerone (MDPV), 
methylone, methcathinone, methedrone and butylone, were 
less frequent. These drugs are recreational stimulants similar 
in structure and clinical effects to amphetamines. During 
2009/10 cathinones were not controlled under misuse of drug 
regulations*, and were freely available and inexpensive for 
purchase from shops and over the internet. 
The NPIS has also been monitoring enquiries relating to other 
newer stimulants, including TFMPP and 2C-B. These agents 
continue to account for a very small proportion of all enquiries 
(Figure 4.5).
Longer term trends are presented as proportions of the total 
numbers of calls received or TOXBASE accesses made each 
year. This adjustment is needed to take into account increases 
in overall TOXBASE accesses and reductions in telephone 
enquiries that have occurred over the years.
Activity relating to cocaine had been increasing, as indicated 
in previous annual reports, but has reduced in the last year. 
One reason may be users switching to other stimulants, 
especially mephedrone. There has also been a reduction in 
telephone enquiries for MDMA and other amphetamines 
in recent years, although TOXBASE activity has not reduced 
(Figures 4.6 and 4.7).
Increases in activity have also been observed for ketamine, 
GBL and benzylpiperazines (BZP), although enquiries relating 
to these substances remain less common. The proportion 
of NPIS activity relating to heroin and LSD has declined 
(Figures 4.6 and 4.7). 
FIGURE 4.5  Telephone enquiries and TOXBASE accesses relating to selected drugs of misuse in 2009/10
*  Mephedrone and many other cathinones were classifi ed under the 
Misuse of Drugs Act as Class B controlled drugs in April 2010.
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NPIS data on drugs of misuse continue to be used to help 
inform policy. During the year reports have been provided by 
the NPIS to the Advisory Council on Misuse of Drugs about 
FIGURE 4.7  TOXBASE sessions relating to selected drugs of misuse other than Class A drugs (data for 2002–2003 by 
calendar year; subsequent data by fi nancial year)
cathinones and organic nitrites (‘poppers’). Mephedrone 
enquiry statistics have also been provided to the European 
Monitoring Centre for Drugs and Drug Addiction.
FIGURE 4.6  TOXBASE sessions relating to selected Class A drugs of misuse (data for 2002–2003 by calendar year; 
subsequent data by fi nancial year)
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4.3  Pesticide Poisonings
In previous years the NPIS report has provided detailed data on 
pesticide exposures. This year we are concentrating on severe 
cases. During 2009/10, 497 telephone enquiries involving 
pesticides were reported to the NPIS. Of these, 13 (3%), were 
graded as severe by the NPIS using the poisoning severity 
score, or were fatal.
Four exposures were reported to result in death. These 
patients were all adults (two male). Three exposures were due 
to deliberate self-harm. One case was accidental and related 
to unsafe storage of a herbicide. All but one of these deaths 
was associated with herbicides, one being related to the 
withdrawn product paraquat. One case related to exposure to 
an organophosphate pesticide.
Nine severe cases were reported. Of these, the majority were 
adults (eight cases). Eight patients were male. In contrast 
to deaths, only three of the severe exposures were due to 
deliberate self-harm and six were accidental.
The three cases of deliberate self-harm exposures involved 
herbicides or organophosphate pesticide. The six accidental 
exposures involved amitraz, endosulfan, organophospate 
(unspecifi ed), paraquat, phostoxin with chlorpyrifos, and 
wood preservative.
One accidental exposure was occupational and occurred 
while the product was in use by the patient. Two exposures 
took place as a consequence of application but not at the 
time of use, one was due to unsatisfactory storage and 
one exposure was an alleged malicious poisoning by a third 
party. In one case the circumstances were unknown and the 
enquirer was trying to rule out pesticide exposure in a brain-
damaged patient.
As in previous reports the majority of pesticide exposures 
reported to the NPIS are accidental and appear to cause little 
in the way of ill-health.
4.4  Quinine Poisonings
Quinine is used extensively in the UK for the management of 
leg cramps, although its effi cacy is generally thought to be 
limited. The MHRA recently issued a caution on its use*.
The main concerns in overdose are the high toxicity of this 
agent, particularly in children, and its association with blindness 
and cardiac arrhythmia.
Telephone enquiries to the NPIS are logged on the UKPID 
system. It has been possible to search this systematically across 
all units since 2008. In 2008/09, the NPIS was contacted 
for information on 126 cases relating to quinine toxicity. In 
2009/10 the number of incidents rose slightly to 133 cases.
When the data for both years are considered together, 
173 (around 70%) of enquiries involved patients ingesting 
quinine alone (or combined with alcohol). Accidental 
exposures were documented in 34 cases, 119 cases were 
reported as therapeutic errors resulting in excess quinine 
ingestion, and 97 cases were documented as deliberate self-
harm acts.
During these two years, 37 cases exhibited cardiac symptoms, 
32 cases developed visual symptoms and 29 cases presented 
hearing disturbances. Visual disturbances were a more 
common complication in those under 50 years of age, but 
the majority of exposures were in those over 50. This is the 
age group for which quinine is prescribed. This illustrates 
the problem that arises when quinine is taken as a self-harm 
action, often by those not normally prescribed the drug. It is 
diffi cult to predict outcome in quinine poisoning, and visual 
loss may vary from complete blindness to various degrees 
of visual fi eld loss which is permanent. In 2009/10 there 
were two deaths reported to the NPIS in which quinine was a 
component of an overdose in an act of self-harm.
The NPIS would encourage physicians to follow MHRA advice in 
limiting prescription to those who benefi t and warning of the 
risks of accidental exposures in children and younger adults.
*  Drug Safety Update Volume 3, Issue 11, June 2010: www.mhra.gov.uk/
Publications/Safetyguidance/DrugSafetyUpdate/CON084655, accessed 
June 2010
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4.5  Tricyclic Antidepressants
Antidepressants are commonly prescribed within the UK. 
They offer the opportunity to treat a potentially devastating 
and life-threatening illness, but also offer a potential source of 
harm to patients who may wish to harm themselves due to 
their depression. 
Some antidepressants are more toxic in overdose than others. 
For example, the tricyclic group of antidepressants (TCAs) and 
other related antidepressants are considerably more toxic in 
overdose than selective serotonin reuptake inhibitors (SSRIs). 
Some cyclic antidepressants – for example, amitriptyline 
and dosulepin (dothiepin) – are more toxic than others. 
When antidepressants are equally effective, it is preferable to 
prescribe those less toxic in overdose. The pattern of self-
poisoning with antidepressant drugs is therefore of interest as 
alterations in prescribing practice could infl uence the outcome 
from self-poisoning.
Data from UKPID show that telephone enquiries to the NPIS 
concerning antidepressants are common, accounting for 9% 
of enquiries to the service. The demographics of patients who 
self-poison with antidepressants differ substantially from that 
seen for the majority of telephone enquiries to the NPIS, with 
a smaller proportion of enquiries concerning children and the 
majority being intentional overdoses involving middle-aged 
adults (Figure 4.8). 
TOXBASE accesses concerning antidepressants continue to 
increase. SSRIs are the commonest antidepressants involved 
and the trend towards increased hits for SSRIs continues. This 
refl ects the changes in prescribing practice for antidepressants 
in recent years for the UK. SSRIs are less toxic in overdose than 
the cyclic antidepressants.
There has been little change in the absolute number of 
TOXBASE accesses, with around 20,000 accesses occurring 
each year (Figure 4.9). SSRIs are the antidepressant drugs most 
commonly involved in telephone enquiries.
Within the TCA group, amitriptyline and dosulepin (dothiepin) 
are the commonest drugs taken in overdose (Figure 4.10). 
Unfortunately, they are also amongst the antidepressants that 
are most toxic. 
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FIGURE 4.9  TOXBASE accesses to different antidepressant 
types from 2005/06 to 2009/10
FIGURE 4.8  Age of patients reported in telephone enquiries 
involving antidepressants in 2009/10
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4.6  Carbon Monoxide
Despite public awareness campaigns, carbon monoxide 
poisoning continues to be an important preventable cause of 
morbidity and mortality in the UK. During 2009/10 there were 
386 telephone enquiries to the NPIS regarding confi rmed or 
suspected carbon monoxide exposure; 290 of these related 
to incidents, while 96 enquiries were for information only. In 
39 enquiries multiple individuals were involved, so that the 
total number of patients was at least 403 (in some cases 
the number of individuals exposed was not known). The 
maximum number of individuals exposed in a single incident 
was 17. This involved residents in rented accommodation in 
which the carbon monoxide detector gave an audible alarm; 
subsequent investigation resulted in the central heating boiler 
being condemned.
The seasonal variation in the numbers of telephone enquiries 
relating to carbon monoxide poisoning for 2008/09 and 
2009/10 is shown in Figure 4.11. This demonstrates the 
reduced frequency of enquiries in the summer months, 
presumably due to reduced use of heating appliances. In 
addition, an increased number of enquiries in the winter 
months of 2009/10 compared to the previous year has been 
recorded. This may be related to the particularly harsh winter 
of 2009/10.
Most enquiries (240 of 290 or 83%) during 2009/10 involved 
carbon monoxide exposure at home, compared to just 8% 
occurring in the workplace and 4% reported in a public area. 
The suspected source of carbon monoxide in the domestic 
setting is known in 71% of cases; central heating boilers were 
implicated most often (Figure 4.12).
Of the 290 enquiries, 266 were reported to be accidental, 
eight were deemed intentional and, in the remaining 16, the 
intention was uncertain but was probably accidental in ten. 
Of the 266 accidental exposures, 244 had a poisoning severity 
score of 0 or 1 (minor toxicity) at the time of the enquiry, 
nine had features of moderate toxicity (PSS 2), and fi ve were 
graded PSS 3 indicating features of severe poisoning; a PSS was 
unavailable in the remaining eight enquiries. 
All fi ve severe cases involved patients who had been exposed 
to carbon monoxide through smoke inhalation during a 
domestic fi re, so factors such as thermal injury may also 
Antidepressant poisoning remains a major source of toxicity 
within the UK. Although the proportion of enquiries related to 
more toxic drugs is falling, the actual number of enquiries for 
the more toxic classes of drugs has changed little.
FIGURE 4.10  Antidepressants most commonly involved in 
telephone enquiries and accessed on TOXBASE in 2009/10
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FIGURE 4.11  Telephone enquiries regarding carbon monoxide exposure received each month 
in 2008/09 and 2009/10
FIGURE 4.12  Suspected source of carbon monoxide 
exposure in a domestic environment in 2009/10
have contributed to their features. Carboxyhaemoglobin 
concentrations in these patients ranged from 4.9–38%. 
Follow-up was attempted in all cases: two patients recovered 
completely, one survived but suffered hypoxic brain injury and 
in the remaining two cases follow-up information could not 
be obtained. 
Of the eight intentional exposures, six involved attempts at 
suicide using vehicle exhaust fumes, one was an attempt 
at suicide which involved the lighting of a barbeque in a 
confi ned space, and one involved the inhalation of carbon 
monoxide from a cylinder. Two of these patients presented 
with signifi cant poisoning, with carboxyhaemoglobin 
concentrations of 41.6% and 29.7%; the remaining patients 
displayed only minor features. 
In three further cases involving victims of house fi res, the 
circumstances of exposure were classifi ed as ‘unknown’ 
but it was considered possible that the fi res had been 
started deliberately. Carboxyhaemoglobin concentrations at 
presentation were 14.8%, 20% and 60%; the patient with the 
highest concentration died.
Central heating 
     boiler 47% 
Domestic fire 18%
Gas fire/    
gas heater 10% 
Car exhaust 9% 
Blocked/damaged
chimney 4%
Solid fuel stove/
barbeque 4% 
Coal fire 3%
Gas cooker 2%
Faulty appliance 
not specified 2%
Other 
1%
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4.7 Alcohol-containing Hand Gels
There has been increasing concern in recent years about 
the transmission of infections including Methicillin Resistant 
Staphylococcus Aureus (MRSA), particularly in healthcare 
establishments. As part of infection control measures, alcohol-
containing hand gels have been made more readily available. 
If ingested these can produce toxic features.
Telephone enquiries about these agents remain uncommon 
in the UK with only 119 received during the year. However, 
this represents an increase of 33% from last year. The majority 
of these calls involved children aged fi ve years or less, with 
a second peak being seen for adults in their third decade 
(Figure 4.13). 
FIGURE 4.15  TOXBASE accesses to alcohol-containing hand 
gels from 2005/06 to 2009/10
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FIGURE 4.14  Telephone enquiries involving alcohol-
containing hand gels by place of use in 2009/10
FIGURE 4.13  Telephone enquiries concerning alcohol-
containing hand gels by age of patient in 2009/10
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Whilst most exposures (64 cases or 54%) occurred in the 
home, a substantial number (41 cases) occurred in healthcare 
facilities (Figure 4.14). Exposures at home were largely 
accidental and involved children, whilst those in adults more 
commonly occurred in healthcare facilities including hospitals, 
GP surgeries and care homes where the availability of the 
product and an intention to consume it deliberately contribute 
to the greater number of exposures.
Ingestion was the most commonly reported route of exposure, 
whilst eye contact was reported in 11 cases.
Whilst TOXBASE does not record the reason a particular 
information page has been accessed, it does show that the 
rate of enquiries concerning these gels has been increasing in 
recent years (Figure 4.15). 
In conclusion, alcohol-containing hand gels are a potential 
source of toxic exposure and care is required in the storage of 
these products near vulnerable patients.
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As a frontline clinical service it is essential that the NPIS has 
robust clinical governance mechanisms in place to ensure 
that the information and advice provided are of the highest 
possible standards and meet the requirements of our 
users. These mechanisms are defi ned in detail in a series of 
operational procedures that are available to all NPIS staff on 
TOXBASE. They include appropriate induction, initial training 
and appraisal of staff, national arrangements for continuous 
professional development, access to high quality information 
sources, early peer review of enquiry answers, and continuous 
support from senior staff including 24-hour availability of a 
consultant clinical toxicologist. Reporting and review of critical 
incidents, complaints and near misses allows sharing of lessons 
learned throughout the service. Views of our users are sought 
by quality assurance exercises encompassing use of TOXBASE, 
the telephone enquiry services for NPIS and UKTIS, and of 
enquiries referred to a consultant.
5.1  Analysis of Critical Events
All NPIS staff are able to report critical events or near misses 
and any complaints or observations on the quality of the 
service are treated under the same system. Critical events are 
examined by the Director of the originating unit in the fi rst 
instance and then reviewed at the Clinical Standards Group 
meeting where recommendations on further actions are 
made. If urgent changes are required, there are mechanisms 
available for rapid discussion amongst the NPIS units and 
implementation of changes nationally.
During 2009/10, nine critical incidents were reported and 
discussed by the Clinical Standards Group. In none of these 
was it identifi ed that the NPIS had provided inaccurate or 
inappropriate advice, but in six cases changes were made to 
the relevant TOXBASE entry in order to make the advice clearer 
for healthcare professionals to follow.
In addition, there were several incidents involving technical 
problems with telephone routing which required discussion 
with the telecommunications provider for their resolution.
5.2 Quality Assurance Exercises
TOXBASE
To obtain formal quality assurance on TOXBASE from users an 
online quality assurance questionnaire was placed on TOXBASE 
during March 2009.
An automated system was designed to ask a selection of users 
to complete and submit short quality assurance forms during 
their online session. Invitations can be set to be generated 
between every two and fi fteen database logins and this 
number was varied throughout the year until a return rate of, 
on average, around three to fi ve per day was achieved. 
A total of 1191 returns were received between 1 April 2009 
and 31 March 2010. The respondents were NHS Direct/NHS 24 
staff (333), NHS nurses (289), junior hospital doctors (230), 
pharmacists (65), hospital consultants (76), ambulance staff/
paramedics (55) and general practitioners (44). The remaining 
154 indicated another designation – these included middle 
grade doctors and biomedical scientists.
On type of enquiry, 590 users reported that they primarily 
used TOXBASE for ‘routine enquiries’, 182 for ‘complex 
enquiries’ and 419 for a ‘triage decision’. On frequency of 
use, 449 reported using TOXBASE daily, 498 weekly and 
244 accessed it only occasionally.
Users were asked to grade a series of statements on a scale 
of 1–6, where 1 was disagree completely and 6 was agree 
completely. Satisfaction scores were high (Table 5.1).
TABLE 5.1  Summary of user satisfaction scores
Rank Question
Satisfaction 
score*
1 I had confi dence in the information 
for my query
92.9
2 Logging on to the database was easy 85.1
3 The information was suffi cient for 
managing this case
83.7
* Satisfaction score is the proportion of respondents who agree 
‘completely’ or ‘a lot’
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When asked to indicate their overall satisfaction with TOXBASE 
on a scale of 1–6, where 1 was poor and 6 was excellent, 1033 
(87%) scored either 5 or 6.
Users commented on several issues, including IT problems 
and diffi culties in searching the database. Where users 
provided contact details responses were made to specifi c 
queries and comments; however, most users chose not to 
provide contact details. Users were also directed to the help 
section on TOXBASE where a guide to searching is provided, 
and to the TOXBASE e-learning module, available at 
www.toxbase.co.uk. 
User suggestions are considered and discussed at the TOXBASE 
Editing Group and NPIS Clinical Standards Group meetings. 
Issues specifi c to entries are dealt with as they arise.
In summary, the majority of respondents reported that use 
of TOXBASE was easy and that it provided the information 
they required. The questionnaire has improved feedback to 
the NPIS and the TOXBASE Editing Group and has allowed 
improvements to be made to the search facility.
Further quality assurance returns on TOXBASE will be used to 
monitor progress and feedback to the service on these issues 
and aspects of data content and presentation.
Telephone information service 
Since 2002 the NPIS units have collected information on user 
satisfaction with the telephone service, to establish if it is 
meeting the needs of their users and to identify and address 
problems, both internal (e.g. diffi culties accessing the service 
or inappropriate advice) and external (e.g. inadequate access 
to TOXBASE or use of referral protocols). 
This report provides the results of the stakeholder quality 
assurance questionnaire exercise for 2009/10, the seventh 
national exercise to be conducted in accordance with the 
national contractual arrangements with the HPA.
Questionnaires were sent to a sample of callers, with the 
sample size intended to be at least 4% of all telephone 
enquiries in each unit, with the exception of Edinburgh, which 
is required to survey a larger proportion in order to obtain 
an adequate sample size, because it takes fewer telephone 
enquiries. A common method of random allocation of calls for 
stakeholder feedback was used.
Data are presented for the period April 2009 to March 2010. 
Equivalent fi gures for 2008/09 are provided in parentheses for 
comparison. During 2009/10, the four NPIS units answered 
52,065 enquiries [56,185] that involved a specifi c patient 
and sent out 2,273 [2,239] questionnaires, a 4% sample 
overall. There were 987 [1,016] responses with a response 
rate of 43% [45%], which is typical for surveys of this type. 
The numbers of questionnaires sent out and returned remain 
comparable to previous years. 
The designation of respondents refl ects the users of the 
service (45% medical and 55% non-medical staff). During 
2009/10 the proportion of callers accessing TOXBASE before 
ringing the service was similar to that in the previous year.
For those accessing TOXBASE fi rst, the telephone enquiry 
was most often made because, as in previous years, they 
considered that there was too little information available on 
TOXBASE to answer their specifi c enquiry (60%) [62%] or 
that there were special circumstances (31%) [25%]. However, 
during 2009/10, there has been a reduction in the proportion 
of respondents who considered that the information on 
TOXBASE was inadequate or that they could not interpret it. 
In keeping with previous trends, there has been a continued 
reduction in respondents reporting local protocols requiring 
them to make a telephone enquiry, or making enquiries 
because information on TOXBASE appeared to confl ict with 
other information. 
In those who did not access TOXBASE fi rst, the proportion who 
did not know what TOXBASE was increased to 36% [22%]. As 
previously, most respondents in this group were GPs. Although 
access to TOXBASE continues to improve, with only 18% [28%] 
of respondents reporting that they do not have access, a 
number of users still experience diffi culty logging on (11%) 
[16%]. The numbers of people reporting that they have not 
been trained has been falling consistently since 2005/06.
To assess the quality of the service as perceived by users, 
respondents were asked to what degree they agreed or 
disagreed with a series of statements relating to the particular 
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enquiry they made to the NPIS. Although questions are framed 
differently, in the results high scores always indicate a high 
overall satisfaction rating. 
Respondents showed a high degree of satisfaction in the way 
they answered the various questions posed, especially those 
relating to the politeness of the staff, the relevance of the 
reply, confi dence in the reply, and the amount of information 
provided (Table 5.2). Satisfaction scores were lowest with the 
speed of delivery of information and the time taken to answer 
the telephone, although satisfaction scores were still more 
than 85% for both these questions. There was little change in 
the rank order of satisfaction scores compared to last year. 
TABLE 5.2  Summary of satisfaction scores
Rank Question
Satisfaction 
score*
1 The person I spoke to was polite 
and pleasant (agree)
97.6
2 The reply from NPIS was relevant 
and useful (agree)
95.6
3 I had confi dence in the reply I was 
given (agree)
95.3
4 The information was suffi cient for 
my needs (agree)
94.0
5 Once I got through to the Specialist 
in Poisons Information the enquiry 
took too long to be dealt with 
(disagree)
93.1
6 I was given too much information 
(disagree)
91.4
7 I had to wait a long time before the 
phone was answered by a Specialist 
in Poisons Information (disagree)
89.7
8 The information was given to me 
too quickly (disagree)
86.9
*Satisfaction score is the proportion of respondents who agree 
(or disagree) ‘completely’ or ‘a lot’
Across all items the quality of service has been maintained 
since 2004/05 (Figure 5.1) and evidence of improvement in 
perceived quality has been observed for the following:
• ‘I had to wait a long time before the phone was answered 
by a Specialist in Poisons Information’ (disagreed: 90% in 
2009/10, 85% in 2004/05)
• ‘The information was given to me too quickly’ (disagreed: 
87% in 2009/10, 77% in 2004/05)
Because of variations in response rate and limited sample size, 
small differences in results between the units may be diffi cult 
to interpret. Formal statistical comparisons have not been 
performed, although 95% confi dence intervals are supplied for 
the overall quality scores. 
The patterns of enquiries by professional grouping are broadly 
similar between units, although, as in previous years, a higher 
proportion of respondents to the Edinburgh unit were GPs and 
a lower proportion were from NHS Direct/NHS 24.
Failure to access TOXBASE before calling the NPIS was 
more common for callers to Edinburgh than for the other 
three units, which may refl ect the increased numbers of GPs 
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FIGURE 5.1  Overall quality scores (with 95% confi dence 
intervals) for the NPIS units expressed as the percentage 
of respondents scoring 5 (   ) or 6 (   ) out of a possible 6. 
Non-respondents are excluded from the denominator
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sampled by the Edinburgh unit. Ignorance of TOXBASE was 
most common in respondents to Newcastle; this may refl ect 
the high proportion of enquiries from London and the South 
East where historically less use has been made of TOXBASE. 
Protocols to ring the NPIS for all cases of poisoning are now 
infrequently reported but appeared to be more common from 
respondents to the Birmingham unit.
All units had a satisfaction rating of over 90% for all questions, 
except that satisfaction about waiting times was less for 
enquirers to the Newcastle and Birmingham units, the 
time taken to handle enquiries once answered (Edinburgh), 
information being provided too quickly (all units), and being 
given too much information (Edinburgh). 
The proportions of respondents indicating high overall 
satisfaction scores (Figure 5.2) were above 90% for all units, 
with the rank order being Birmingham (99%), Newcastle 
(96%), Cardiff (96%) and Edinburgh (94%). 
In summary, respondents continue to have a high level of 
satisfaction with the service, both overall and for each of the 
specifi c issues under enquiry. Satisfaction was slightly less 
relating to information being delivered too quickly and the 
time taken to answer the telephone, but responses to all of 
these have improved since 2002. No specifi c issues were 
identifi ed where there has been a reduction in satisfaction 
over time.
In the light of these results, the NPIS units should continue to 
raise the profi le of TOXBASE, particularly in the primary care 
setting, and encourage its widespread availability. TOXBASE 
entries should increasingly highlight the need to discuss more 
complex cases with NPIS specialists and provide clear guidance 
on the need for consultation. NPIS staff should take particular 
care to provide information at an appropriate pace to meet 
the enquirer’s needs.
Consultant referrals
Last year’s annual report included two quality assurance 
exercises (started in January 2009), one to callers who spoke 
to a consultant and one to the consultant taking the enquiry, 
to assess the effectiveness of the system. These exercises 
continued for part of 2009/10 and returns from this year are 
reported here with an additional exercise involving specialists 
in poisons information (SPIs).
Response from enquirers referred to NPIS consultants
There were 37 replies received during 2009/10 (14 consultants, 
14 junior doctors, three GPs, one nurse and fi ve others). Only 
one respondent did not have a clear recollection of the call. 
Seven had asked to speak to a consultant, 27 spoke to a 
consultant because the SPI advised it, two said that there was 
another (unstated) reason, and one said that they requested it 
and that the SPI advised it.
Respondents were asked how long it took before they 
spoke to the consultant. Of the 36 who could remember, 
33 replies gave a time of less than one hour, one said less than 
two hours, one said three hours and the last said ‘same day’. 
No respondent said that any delay affected patient care.
Enquirer satisfaction scores for the service that respondents 
received from the consultant referrals were high (Table 5.3) 
and overall on a scale of 1–6, where 1 was very poor and 6 was 
excellent, respondents scored the service at 5.6.
FIGURE 5.2  Overall quality scores (with 95% confi dence 
intervals) for the NPIS units in 2009/10, expressed as the 
percentage of respondents scoring 5 (   ) or 6 (   ) out of a 
possible 6
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TABLE 5.3  Summary of enquirer satisfaction scores
Rank Question
Satisfaction 
score*
1 The person I spoke to was polite 
and pleasant (agree)
94.6
1 I had confi dence in the advice I was 
given (agree)
94.6
3 The advice from the NPIS 
Consultant was relevant and useful 
(agree)
86.5
3 The information was suffi cient for 
my needs (agree)
86.5
5 The information was given to me 
too quickly (disagree)
81.1
5 I was given too much information 
(disagree)
81.1
* Satisfaction score is the proportion of respondents who agree 
(or disagree) ‘completely’ or ‘a lot’
Response from NPIS consultants who have taken 
clinician referrals
There were 69 replies received between April and July 2009. 
In 66 cases the consultant had a clear recollection of the 
call. In 28 cases the caller asked to speak to a consultant, 
in 19 cases it was the consultant’s decision after discussion 
with the SPI, and in 14 cases the SPI suggested it. In a further 
three cases the consultant could not remember; in one case 
the consultant happened to be in the room at the time of the 
enquiry; in one case there was another reason (unstated); in 
one case the consultant was unsure if he or the SPI had felt a 
direct discussion was necessary; and fi nally in two cases the 
question was not answered.
Consultants reported that they contacted enquirers rapidly: 
in 51 cases this was within fi ve minutes, three could not 
remember the exact timing and the remainder were within 
25 minutes. Delays in responding to the caller were due mainly 
to delays in reaching the doctor at the hospital, or occasionally 
having to perform further research on unusual substance(s) 
involved before answering.
Consultants were generally happy with the appropriateness of 
referral, the way information was presented to them, and the 
service they had provided (Table 5.4). Consultants were asked 
to grade the service they provided on a scale of 1–6, where 
1 was very poor and 6 was excellent. The average was 5.4, 
which compares well with the average of 5.6 as assigned by 
callers for the overall quality of the service. 
TABLE 5.4  Summary of NPIS consultant questionnaire 
scores
Rank Question
Satisfaction 
score*
1 The person I spoke to was polite 
and pleasant (agree)
97.1
2 The referral to an NPIS Consultant 
was appropriate (agree)
95.7
3 The information I provided 
appeared to be understood (agree)
94.2
4 The information from the enquirer 
was well presented by the SPI 
(agree)
82.6
5 I obtained additional material 
from the enquirer that they had 
not initially reported or been asked 
(agree)
34.7
* Score is the proportion of respondents who agree 
‘completely’ or ‘a lot’
Response from specialists in poisons information who 
have referred calls to NPIS consultants
It was agreed by the Commissioner that NPIS specialists 
in poisons information would also be surveyed on their 
experience of call referral. There were 114 replies received and 
in all the SPI had a clear recollection of the call. In 11 cases 
the enquirer asked to speak to a clinician; in 58 the enquiry 
met the NPIS criteria for referral to an NPIS consultant; and 
in two cases both these applied, i.e. the clinician asked for 
the referral and it met the criteria. In 41 cases there was 
some other reason (unusual case or specifi c enquiry which 
the SPI could not answer, or the clinician had already spoken 
to an NPIS consultant); and in two cases the question was 
not answered. 
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SPIs were reported to contact NPIS consultants rapidly: in 
71 cases this was within fi ve minutes, for one case the time 
could not be remembered, and the remainder were within 
35 minutes. Delays to referring the call included having to 
check multiple calls about the patient and having to use more 
than one method (e.g. pager and mobile) before reaching 
the consultant. NPIS consultants carry mobile phones but 
these are sometimes inaccessible in hospital buildings due to 
signal screening.
In 39 calls the clinician spoke to the caller directly and in 
75 cases the SPI relayed the information. In 89% of enquiries 
SPIs were satisfi ed that this was appropriate. 
SPIs were generally happy with the handling of the call and 
on a scale of 1–6, where 1 was very poor and 6 was excellent, 
scored the service at 5.5. 
TABLE 5.5  Summary of NPIS SPI questionnaire scores
Rank Question
Satisfaction 
score*
1 It was diffi cult to contact the 
clinician (disagree)
95.6
1 The clinician took a long time to 
answer (disagree)
95.6
3 I had confi dence in the advice given 
to me by the clinician (agree)
95.5
4 The information given to me by the 
clinician was relevant and concise 
(agree)
95.4
4 The advice was relevant and concise 
(agree)
95.4
6 The clinician I spoke to was polite 
and pleasant (agree)
89.5
7 The clinician requested more 
information than I had available 
(disagree)
87.4
* Satisfaction score is the proportion of respondents who agree 
(or disagree) ‘completely’ or ‘a lot’
Summary
In conclusion, callers, consultants and SPIs all rated the service 
provided highly, and interdisciplinary working was generally 
of a high standard as judged by these anonymised scoring 
systems. Most callers thought the advice was relevant, useful 
and suffi cient, and they had confi dence in the reply. Some 
callers thought too much information was given too quickly, 
but the majority were satisfi ed. 
Consultants generally thought the referrals were appropriate 
and the information was well presented by the SPIs. They often 
obtained additional information while speaking to the caller 
that had not been acquired earlier. They considered that the 
callers generally understood the information they were given. 
Callers, consultants and SPIs were all generally considered 
polite and pleasant. Callers appeared to consider that it took 
longer for the consultant to contact them, while consultants 
usually thought they had contacted the caller very quickly, but 
there were occasional delays in the SPI contacting the NPIS 
consultant. In some units it is now possible to pass the caller 
directly to the consultant, while the SPI also stays on the line 
for recording purposes. This is to be extended to all units. As all 
responses were anonymised, it is not possible to link enquirer 
and NPIS consultant responses and assess their correlation.
The small numbers involved means these data should be 
interpreted with caution. The audit of enquirers being put in 
contact with NPIS consultants will be repeated later this year.
UKTIS telephone enquiries
A random sample of 240 (6%) enquiries, 20 per month, made 
directly to UKTIS was selected for quality assurance monitoring. 
Questionnaires were sent out to enquirers between one and 
four weeks after the enquiry. As of May 2010, 98 (41%) forms 
had been returned. The responders were hospital consultants 
(12), junior hospital doctors (3), pharmacists (44), GPs (30), 
nurses (6), specialist registrar (1), Research Fellow in Fetal 
Medicine (1), and health advisor (NHS Direct) (1). The majority 
of respondents (39%) had used the service between one 
and fi ve times previously, with a further 20% being fi rst-time 
enquirers (Figure 5.3).
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FIGURE 5.3  Number of times telephone enquirers had used 
UKTIS in the past year
Respondents were asked to rate their overall satisfaction with 
the service received from UKTIS in answering their enquiry. 
On a scale of 1–6, where 1 was very poor and 6 was excellent, 
90 (92%) scored the service as very good (point 5) or excellent 
(point 6). 
Users were asked to grade a series of statements using the 
same 1–6 scale. Once again, satisfaction scores were high 
(Table 5.6). 
TABLE 5.6  Summary of UKTIS enquirer satisfaction 
scores
Rank Question
Satisfaction 
score*
1 The person I spoke to was polite 
and pleasant (agree)
93
2  I had confi dence in the reply I was 
given (agree)
90
3 The information was suffi cient for 
my needs (agree)
82
4 The reply from UKTIS was relevant 
and useful (agree)
80
5 Once I got through, the enquiry 
took a long time to be dealt with 
(disagree)
75.5
5 The information was given to me 
too quickly (disagree)
75.5
* Satisfaction score is the proportion of respondents who agree 
(or disagree) ‘completely’ or ‘a lot’
Ninety-four (96%) respondents reported that they found it 
easy to contact UKTIS and the majority were happy with the 
amount of information they received from the service (95%). 
All the respondents said they would use the service again.
The last section of the questionnaire invited the enquirers to 
make comments and suggestions on how the service could 
be improved. This section was completed by 37 (38%) of the 
respondents. The majority of the comments made refl ected 
satisfaction with the high quality service provided.
Never 20%
Once 18%
Between one and    
five times 39%
More than 
five times 23%   
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It is now fi ve years since the National Poisons Information 
Service adopted a national networked service with a single 
national telephone number and shared rota arrangements 
between the four NPIS provider units. In this section we review 
changes that have taken place during this period.
6.1 Telephone Service and Rotas
In July 2005 a networked NPIS telephone service was 
introduced with a single national number available to all 
medical professionals in the UK. Prior to this change the NPIS 
units in Birmingham, Cardiff, Edinburgh and Newcastle offered 
independent 24-hour services to their local users.
Poisons information is available by telephone from all four units 
between the hours of 08.00 and 20.00, Monday to Friday, 
with two units being available in the daytime and evenings 
during weekends and public holidays and one unit remaining 
open overnight.
During the daytime each unit handles calls from its designated 
geographical area, although in the event of all telephone 
lines being busy, a sophisticated ‘hunt and pick’ system 
forwards calls automatically to a unit where a line is available. 
This automatic routing has resulted in a more effective 
call-answering system. Outside core hours the Birmingham, 
Cardiff and Newcastle units participate in a national rota which 
is supported by a call-switching programme provided by 
British Telecom.
A business contingency plan has been introduced to ensure 
the 24-hour-a-day integrity of the service. Should any of 
the units participating in the out-of-hours rota be unable to 
accept enquiries by their landlines then calls can be diverted 
to designated mobile phones using the BT ‘Follow Me’ service. 
This ensures service delivery irrespective of the location of 
specialists in poisons information.
6  Five Years of UK-wide Development 
and Joint Working
6.2 UKPID and Surveillance
Information given during telephone enquiries to the NPIS is 
recorded on to an electronic database, the United Kingdom 
Poisons Information Database, UKPID. Historically, each NPIS 
unit recorded its own data locally. However, data collection was 
not uniform nationally, with three units using UKPID and the 
fourth a proprietary local database.
With the development of a more closely networked service, 
the need for harmonised data collection became more 
important to support UK resilience and the opportunity for 
undertaking surveillance at a national level became possible. 
For more than two years, all NPIS units have been collecting 
data using UKPID which are encrypted and stored on a secure 
database. These data are available to the NPIS units in near 
real time, which facilitates continuity of patient care, should 
advice by more than one unit be required. Older historical 
data remain available by interrogating the central server in 
conjunction with a local server.
The UK is thought to be unique in that it is the only country 
which records national data from all poisons information 
centres in real time, rather than a more limited number 
of core data fi elds. A UKPID user group, consisting of 
representatives from every NPIS unit, meets regularly to ensure 
that the current system works well and to produce advice on 
future developments.
The data concerning telephone enquiries in this report are 
generated from UKPID. Where possible, a full set of data is 
collected during each contact and most data are recorded in 
a harmonised manner in dedicated specialised fi elds, although 
free text fi elds are also available to record, for example, 
complicated details of the medical history. Sometimes not all 
information is available to the NPIS – for example, the age of 
the patient may not be stated. 
Data are collected concerning the reason for the enquiry 
and include the identity and location of the enquirer. Where 
possible, the demographic data for the patient are collected 
and the nature of the putative exposure is recorded. The 
details for the latter may include the name of the substance 
or its ingredients, the amount taken, the route by which the 
exposure occurred, the time of exposure and the location of 
the exposure. In addition, the clinical condition of the patient is 
recorded, together with any prior treatment. 
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A record of the advice given to the caller, either by the 
specialist in poisons information (SPI) or by the consultant 
clinical toxicologist, is also recorded. A judgement is made by 
the SPI concerning the clinical condition of the patient and this 
is recorded on UKPID as a poisoning severity score. Specifi c 
treatments recommended are recorded in a structured format 
to facilitate data interrogation.
Each UKPID record is ‘buddy checked’ for completeness, and as 
a quality assurance measure concerning the advice given.
Some data fi elds are considered essential – for example, the 
source of the enquiry – whilst others are desirable. Audits are 
undertaken to ensure UKPID data collection remains of a high 
quality and that data collection is performed uniformly within 
the NPIS.
UKPID data are being used increasingly to contribute towards 
the evidence base for decisions concerning public health in 
the UK. For example, anonymised data have been provided 
to regulatory authorities to facilitate decisions involving the 
risks and benefi ts of some medicines currently on the market. 
UKPID has also provided data concerning the changing 
pattern of use of drugs of misuse, including cathinones which 
have been marketed recently as potentially ‘legal highs’. In 
addition to being able to provide data concerning the rapidly 
increasing frequency of contact with the NPIS concerning 
these chemicals, it is also possible to interrogate the database 
to provide information concerning the clinical effects of the 
newly seen compounds. Some of these issues are described in 
further detail elsewhere in this report.
It is hoped that future developments to the database will 
enable follow-up data to be stored in a structured and 
harmonised way. This should improve the ability of the NPIS to 
learn from the outcomes of cases upon which advice has been 
given and strengthen the service for the future.
6.3 TOXBASE
TOXBASE is the fi rst point of contact for most enquirers 
using the NPIS. The number of accesses to the database has 
increased steadily since its placement on the internet in 1999, 
and now, on average, an access is made approximately every 
minute and a product download made every 30 seconds. 
Signifi cant work has been done to support this key NPIS 
resource over the last fi ve years, including the requirement 
to update regularly the large number of products entered on 
the database.
The most important development has been the change to a 
new database platform which facilitates more effi cient writing 
FIGURE 6.1  TOXBASE main index page in the mid-1990s and TOXBASE home page in 2008
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and editing of entries. This has allowed the development of a 
series of ‘standard phrases’ that guide clinical management of 
common poisoning scenarios, and common complications of 
poisoning. NPIS Edinburgh is responsible for the overall control 
of the database but the work of writing, editing and reviewing 
database entries is now divided between all four NPIS units.
Draft entries are available on the TOXBASE database for time-
limited review by all NPIS consultants and information staff, 
and in this way a unifi ed position on the management of 
poisons is obtained. This new way of working has allowed us to 
increase the numbers of entries reviewed. All commonly used 
entries are now reviewed annually, and all components of the 
database every four years.
The new software has enabled improved tracking of edited 
and changed entries in the database, thus helping to maintain 
an audit trail. It also allows more fl exibility in outputs for users. 
In this way we now have more active links available and have 
improved the ability for users to provide information to us and 
thus the ability to collect data on enquiries about new drugs 
and compounds of specifi c interest – for example, pesticides 
and drugs of misuse.
Since TOXBASE is used by staff with a variety of healthcare 
backgrounds it is important that entries are clear and easy to 
understand. To this end, increasing numbers of commonly 
accessed entries have ‘Alert Boxes’ prominently displayed 
which give colour-coded details of the likely toxic risk from 
a product, together with an indication of the toxic dose. 
This dose is generally given in milligrams per kilogram body 
weight, and TOXBASE now includes calculators to assist users 
in this conversion. Calculators are also now provided to assist 
in the management of paracetamol poisoning, allowing the 
determination of appropriate doses of antidote based on the 
patient’s weight.
A new development in 2009 was the introduction of ‘Nursing 
Guides’ with suggested care plans for a range of common 
poisonings. These have been developed by nursing staff who 
work in the clinical departments associated with the NPIS units. 
The care plans were downloaded over 7500 times in 2009/10, 
and their use is increasing. We believe they will improve the 
care of poisoned patients across the UK.
The home page of TOXBASE now includes alerts and 
newsfl ashes (Figure 6.2) which are derived from a range of 
sources, including contacts in poison centres internationally 
and UK authorities such as the Department of Health and the 
MHRA. Users can register their contact details so that improved 
follow-up of poisonings involving new or unusual drugs can 
be obtained. All entries also have relevant reference lists and 
direct links to PubMed abstracts of recent papers.
A regular newsletter (Figure 6.3) is published electronically 
and provided to registered users of the database every 
two months. This highlights new developments and changes 
to the database.
TOXBASE is made available under contract to users in the 
Republic of Ireland as part of the HPA agreement with the 
Irish government. Under this agreement, specifi c entries on 
TOXBASE relating to Irish products are included and reviewed 
by colleagues in the Irish Poisons Information Centre in Dublin. 
Under a special agreement with European poison centres that 
are members of the European Association of Poison Centres 
and Clinical Toxicologists, TOXBASE is provided under licensed 
contract to a small number of pharmaceutical companies and 
overseas health providers. This provides a modest source of 
income for the NPIS.
FIGURE 6.2  Newsfl ashes appearing on TOXBASE 
(accessed 23 April 2010)
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The success of TOXBASE has been a remarkable achievement 
for the NPIS and it is now a fundamental component of the 
poisons information service in the UK. None of this would have 
been possible without the support of both colleagues in the 
service and clinicians working in the NHS who have helped 
to refi ne the content of the database by providing feedback. 
The most recent development in this line has been the online 
quality assurance tool which is another feature of the new 
database structure. The user response has been enormously 
positive; full details are provided elsewhere in this report. 
Maintaining this standard will be a challenge for the future but 
we are optimistic that this can be achieved.
6.4 UKTIS
The past fi ve years has been a period of signifi cant growth 
and development of the UK Teratology Information Service 
(UKTIS). Originally staffed by a head of teratology, one scientifi c 
information scientist and a personal assistant, additional HPA 
investment has enabled the appointment of new permanent 
staff to refl ect the substantial workload involved in provision of 
the service. 
A major focus over this period has been the upgrading of the 
UKTIS enquiry and follow-up database to a new ‘state-of-the-
art’ web-based system that will facilitate improved logging 
of enquiries, follow-up of pregnancy outcomes, and analysis 
of data for surveillance. All legacy data, including older data 
previously held as paper records, have successfully been 
migrated to the new database which went live in the latter half 
of 2010.
These developments culminated in the relaunch of the service 
in 2009 as the UK Teratology Information Service (UKTIS), 
previously the National Teratology Information Service (NTIS), 
with a new logo, national telephone number and dedicated 
website (www.uktis.org). The involvement of UKTIS in the 
HPA emergency response to the 2009 A/H1N1v infl uenza 
pandemic has proved instrumental in raising the profi le of the 
service and establishing its new identity.
UKTIS has also focused on increasing its research portfolio, 
at both national and international level, during this period. 
External funding for three research projects supporting 
fi ve further fi xed-term positions, including data administrators 
and senior medical information scientists, has been secured 
during 2009/10. 
FIGURE 6.3  Example of TOXBASE users newsletter
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6.5 Clinical Governance and Audit
The NPIS seeks to provide evidence-based clinical advice that 
is of the highest possible quality and is consistent, irrespective 
of the unit that has issued the advice. It is our intention that 
information should be provided as rapidly as possible and 
should meet the needs of the healthcare professional seeking 
our support.
In order to achieve these aims, the NPIS has developed 
operational procedures which are consistent across all units 
and available at all times to all NPIS staff on TOXBASE. These 
cover all the issues that are important in providing a high 
quality service, including appropriate induction and training of 
staff, referral criteria for consultants, critical incident and near-
miss reporting, and library and other resources for the NPIS 
units. These operational procedures are reviewed regularly and 
updated as required and there is the opportunity for all NPIS 
staff to contribute to that process.
NPIS clinical governance review
In 2007 NPIS underwent an external clinical governance 
review (the Evans Review). That review found that at that time 
the clinical governance arrangements of the service were 
‘perfectly acceptable and in many respects a better level 
than that seen in many NHS units’, although the potential for 
further improvement was acknowledged. Current progress 
in implementing the recommendations of the review team is 
shown in Table 6.1.
TABLE 6.1  Current progress in implementing the recommendations of the review team
Recommendation Summary of progress
1 Maintain a telephone contingence to the BT service ‘Follow-on’ facility to reserve mobile phones 
instituted in NPIS units in 2007
2 Seek, obtain and provide facilities to record, if possible 
electronically, telephone advice to and from NPIS units by 
consultants when on-call
Call recording introduced in all NPIS units in 2008
3 Consider enrolling into the National Call Centre Agency (CCA) to 
provide high quality review of the contact call system
This approach explored but found to be unsuitable
4 Continue to develop the curriculum of competencies for 
specialists in poisons information
Competencies for SPIs developed and published
5 Explore and attempt to register such competencies with a national 
body, such as UKCHIP or HPC
This approach explored but found not to be 
appropriate
6 Continue to lobby the Royal College of Physicians and JRCPTB 
with a view to preparing a syllabus and curriculum for clinical 
toxicology for trainees as an aid to recruitment
Curriculum in clinical toxicology submitted to the 
RCP and JRCPTB in 2009. Not currently approved 
(lack of funding)
7 Continue to provide opportunities and funds for physicians and 
specialists in poisons information to attend joint meetings suitable 
for CPD
Regular national NPIS CPD meetings instituted with 
resource for attendance of SPIs and consultants
8 Encourage further discussion with GSTFT and to afford a spirit of 
rapprochement, but not at the expense of the existing service
Contract negotiated with GSTFT for consultant 
support for NPIS, starting 2009
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6.6 Education and Continuing 
Professional Development (CPD)
Developing the skills and professional expertise of the NPIS 
workforce is an important challenge. To address this issue the 
NPIS now organises a regular series of continuing professional 
development (CPD) programme meetings. These are hosted 
by each NPIS unit in turn and by the NPIC in Dublin, taking 
place three or four times a year. An NPIS consultant leads on 
the development of the programme and all presentations are 
available to NPIS staff on the TOXBASE website. Meetings are 
themed around specifi c topics, and presentations are given by 
internal and external speakers; Figure 6.4 shows an example of 
a CPD programme. 
There is increasing demand to attend these meetings from 
those not immediately associated with the NPIS. In response to 
this, a series of educational events is being organised with the 
College of Emergency Medicine on poisons-related topics. The 
fi rst of these will be held in 2010.
All NPIS staff undergo regular appraisal and career 
development planning. Staff have opportunities to attend 
and are encouraged to present at national and international 
academic meetings of relevance to their roles. NPIS staff are 
regularly invited to speak at educational events nationally 
and internationally.
Development of the NPIS into a single, unifi ed service 
under the umbrella of the HPA has allowed further work on 
educational initiatives. The fi rst was the development of online 
educational material, initially supported by NHS Education 
Scotland, that was designed to provide users with an 
educational introduction into the structure and function of 
TOXBASE. Subsequently the HPA has funded work to provide 
educational modules on common poisoning scenarios. In 
2010/11 a new module on common chemical poisonings will 
be launched. These are all available on the NPIS educational 
website, www.TOXBASE.co.uk.
FIGURE 6.4  Example of an NPIS CPD programme
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e-learning
NPIS Edinburgh fi rst developed an e-learning resource in 
2005 – www.toxbase.co.uk – which went live in September 
of that year. Over 2000 individuals have registered on the site 
between its launch and 31 March 2010.
As mentioned above, the resource was initially designed to be 
used for training new staff at NHS 24 centres on the use of 
TOXBASE, but is also available to NHS Direct staff in England 
and to other interested NHS users. Registration and access 
are free to NHS users, who can work through the site at their 
own pace, save their work, obtain their scores and print a 
certifi cate of completion for their continuing professional 
development fi le. 
Depending upon user type, two levels of the TOXBASE unit are 
available, Level 1 for NHS 24/NHS Direct users and Level 2 for 
emergency department nurses/junior doctors. As of 31 March 
2010, a total of 1962 users had completed the TOXBASE unit. 
Completion of the Level 2 TOXBASE unit represents 1.75 hours 
of study. 
A second ‘Clinical Toxicology’ unit was added to the e-learning 
site in July 2008. This unit contains modules designed to help 
junior doctors and triage nurses improve their knowledge on 
the clinical management of the poisoned patient. Units are 
available on: 
a General Aspects (initial intervention, antidotes, clinical 
syndromes, common dilemmas) 
b Common Poisons (paracetamol, NSAIDs, benzodiazepines)
c Problematic Poisons (tricyclics, SSRIs, calcium channel 
blockers)
d Drugs of Misuse (‘the agitated patient’, ‘an unconscious 
patient’, ‘a drowsy patient’, ‘an unknown substance’). 
Since this unit’s launch 336 users have completed modules. 
Completion of the whole unit represents 3 hours of study and 
again a printable certifi cate is available.
6.7 The Next Five Years
The NPIS units now have fi rmly embedded UK-wide networking 
arrangements for handling telephone enquiries from 
healthcare professionals and for providing consistent, up-to-
date poisons information online on TOXBASE. The current 
national structure offers opportunities for the NPIS to develop 
further in several areas, as funding allows.
1 Service organisation 
A natural reduction in telephone enquiry workload has 
taken place over the last decade as a result of increased 
and improved online access to the information on TOXBASE. 
This has changed the pattern of staff working, allowing the 
specialists in poisons information (SPIs) to increase tasks 
associated with TOXBASE updating when not busy answering 
NPIS telephone queries including: 
a Ensuring that the 14,000 monographs on TOXBASE are 
consistent with current clinical research continues to be the 
major workload for the service
b Developing the use of aggregated data to optimise the 
NPIS contribution to scientifi c and clinical debate 
c Providing timely appropriate NPIS data to government and 
its agencies
d Increasing contributions to appropriate clinical research. 
There is the need to ensure that the NPIS units maintain the 
telephone service to the current high standards but at the 
same time maximise the productivity of SPIs for other work. 
It is also important that users of TOXBASE are not over-reliant 
on online access and that the NPIS continues to ensure 
appropriate use of individualised telephone advice for complex 
poisoning enquiries. Maintaining the correct balance between 
online and telephone advice will continue to be a challenge to 
support and achieve.
Complex telephone routing arrangements allow calls to be 
delivered to an appropriate unit but also allow the rare risk of 
routing errors which can be catastrophic if they occur. Ways to 
simplify the telephone routing arrangements to reduce the risk 
of such errors need to be kept constantly under review.
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2 Consultant support
Considerable resource has been invested in consultant support 
for the NPIS and a single national on-call consultant rota has 
been functioning effectively for several years.
However, the following issues still need to be kept under 
consideration and taken forward in the next fi ve years:
a Senior staff retirements are expected in the next three 
years. Replacements with appropriately trained and 
experienced staff will be diffi cult as the potential pool is 
small. Lack of recognised systematic training programmes 
for clinical toxicology and information scientists has 
hampered the formal development of the sub-speciality 
over recent decades
b Skill mix – until recently NPIS consultants have been all 
adult physicians, usually with accreditation in medicine and 
clinical pharmacology. However, many other specialities 
are relevant to the delivery of the aims of the NPIS service. 
A large proportion of NPIS contacts concern children 
and many poisoned patients are managed in hospital 
emergency departments. The NPIS has achieved some 
limited support with paediatric input to the service 
from consultants based in the accident and emergency 
departments in Edinburgh and Newcastle. This small start 
should help to improve NPIS paediatric advice and also 
increase the visibility and credibility of the service to those 
working in accident and emergency and paediatric settings
c Enhanced training of NPIS staff in environmental toxicology, 
and management of poisoning involving radiation, are 
areas that need addressing to support and enhance 
joint working with specialists in environmental chemical 
and radiation hazards and emergency response to 
environmental disasters.
3 UKPID
It is a priority for the service to develop and fund the next 
version of the poisons database UKPID, following the current 
review of the system. Key modifi cations needed to improve 
the capability of UKPID to support surveillance of poisoning 
include:
a Development of embedded signal-detection 
methodologies for syndromic surveillance
b Introduction of the ability for data to be extracted by 
all units to the same level of complexity, to allow better 
sharing of the information analysis workload between units
c Development of a database suitable for anonymised data 
linkage with other relevant data sources such as hospital 
episode statistics, NHS prescribing data and ONS statistical 
data
d Harmonisation of core datasets with poisons centres across 
the European Union using fully searchable multilingual 
dictionary terms.
4 TOXBASE
TOXBASE is already established as one of the premier 
clinical decision support tools used in the NHS, with more 
than a million product accesses annually. Feedback from 
users confi rm that it is most valued by staff in accident and 
emergency departments for patient management.
Enhancements that need consideration include developing:
a The ability to more closely monitor activity on the database 
automatically and generate alerts for changes in patterns 
of enquiries, particularly for rarer poisons
b Systems that allow more complete collection of 
information about a larger proportion of toxins of special 
clinical interest, their effects and patient outcomes from 
TOXBASE users
c Better search facilities for identifying toxins associated with 
particular patterns of clinical presentation
d Facilities for users to upload their own details, e.g. 
availability of local laboratory assays and antidotes.
5 UKTIS
Enhancements to UKTIS over the past fi ve years have included 
staff and software developments to improve the logging of 
enquiries and support better follow-up data. Over the next 
fi ve years these are expected to deliver better quality data that 
will improve pregnancy outcome information for healthcare 
professionals which will be made available on TOXBASE and 
through peer-reviewed research outputs. 
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Further developments that need to be considered include: 
a Develop the UKTIS website to allow healthcare professionals 
to access reporting forms, monograph summaries and 
information about ongoing research projects directly
b Develop online facilities for pregnant women to provide 
details of exposures and pregnancy outcome directly
c More extensive follow-up of pregnancy outcomes following 
drug or chemical exposure as facilitated by the new UKTIS 
database
d Undertake regional pilots to explore the feasibility of more 
effective methods of data collection
e Reduce loss to follow-up of women by increasing use of 
national patient tracing systems 
f Enhance the visibility of UKTIS amongst key user groups 
such as midwives, obstetricians and paediatricians
g Strengthen links with regulatory bodies and professional 
organisations including international organisations such as 
the European Network of Teratology Information Services, 
the Organisation of Teratology Information Specialists in 
North America and Motherisk in Canada 
h Consider developing a business case to establish a public 
information source of advice on drugs and other exposures 
in pregnancy. 
6 NPIS information provision
Enhancements to UKPID, TOXBASE and the UKTIS database 
allow the NPIS to provide important timely information 
to public health external agencies. The NPIS also supplies 
information to national organisations such as the MHRA 
and ACMD. 
There is a need to:
a Share this workload between units, which requires 
upgrades to software already identifi ed 
b Develop and implement a consistent policy for information 
provision including ensuring recovery of costs as 
appropriate 
c Develop a business case to improved expertise in 
epidemiology within the service to optimise appropriate 
data usage, by the appointment of a scientist with 
expertise in statistics, epidemiology and public health.
7 Clinical governance and audit
The NPIS already has high standards of clinical governance 
involving audit and quality assurance exercises for all the 
types of activity it performs, from immediate checking of 
information provided to detailed stakeholder QA exercises. 
Within the last fi ve years the clinical governance arrangements 
of the service have been endorsed by an independent review. 
Continuous improvement in the systems that ensure the 
quality, safety, review and update of NPIS clinical governance 
standards are an ongoing requirement.
New developments that should be considered include: 
a Enhanced audit of the recordings of individual telephone 
enquiries 
b Enhanced peer review of advice provided by NPIS 
consultants.
8 Education and CPD
It is essential to the quality of the service that NPIS staff are 
properly trained for their roles and that there are opportunities 
for them to improve their knowledge and skills in this specialist 
fi eld. Great progress has been made over the last fi ve years 
in increasing the availability of educational opportunities for 
staff by instituting regular national meetings and by funding 
attendance of appropriate staff at international events when 
these offer important educational opportunities that are not 
available in the UK. 
The NPIS has also provided education on the management 
of poisoning to healthcare professionals outside the service 
and it would be useful to enhance this activity over the next 
fi ve years, with the aims of improving the general care of 
poisoned patients, increasing familiarity with management 
of chemical releases (including deliberate release), improving 
knowledge and use of NPIS services, etc. Educational 
programmes carried out in conjunction with the College of 
Emergency Medicine are an effective way of reaching one key 
user group.
Increased access to educational sessions can also be achieved 
by use of new web-based technology. This would allow staff 
both within and outside the service to access material at a 
place and time convenient to them. 
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9 Research
The evidence base for treatment of poisoned patients is 
relatively small due to the diffi culties in conducting research 
in this patient group. The NPIS units are now well placed to 
obtain external research funding to conduct clinical trials and 
other clinical research in this most vulnerable patient group in 
the UK to optimise treatment and reduce adverse reactions in 
acutely poisoned patients. Successful conduct of such clinical 
trials could pave the way to larger multi-centre, international 
clinical trials to provide the evidence base for the treatment of 
infrequent poisonings. 
Other areas of research include discovery of novel biomarkers 
of both acute and chronic toxicity and the health effect of new 
drugs and chemicals in overdose. 
10 Publicly available information and access
With increasing access to the internet, the general public is 
faced with a large amount of confl icting information about 
drugs and poisons from a variety of sources. Consumer 
pressure to have access to timely and authoritative advice on 
aspects of the toxicity of consumer products and drugs is likely 
to increase. As is already the case in many other European 
countries, there is a case for providing direct access to NPIS 
information to the general public in the UK. Such information 
could be provided online through a tailor-made public advice 
website (e.g. npis.org). Any such public facing advice would 
need to be consistent with TOXBASE advice.
Such reliable advice would support:
a Improved consumer access to reliable information about 
toxicity and specialist advice when required and improved 
satisfaction with the service
b Optimal use of the emergency services
c Reduced referral rates to hospital as shown by the low rates 
of referral resulting from telephone enquiries to the NPIS
d Provision of a platform for poison prevention activities and 
strategies
e Improved data collection on aspects of poisoning especially 
those episodes not resulting in contact with healthcare 
professionals, enhancing the surveillance role of the NPIS to 
underpin appropriate prevention strategy development.
11  Preparation for the London 2012 Olympic 
Games
An NPIS priority for the next two years is to ensure appropriate 
preparation for the 2012 Olympic Games. The NPIS plans to 
ensure an enhanced ‘business as usual’ status for the period 
surrounding the Olympics. The comprehensive NPIS 24-hour 
telephone and internet-delivered information service is already 
provided to registered UK healthcare professionals. The service 
would offer timely advice on the diagnosis, treatment and 
care of patients poisoned as a result of a deliberate release 
or environmental disaster that could be associated with the 
Olympics, whether such events takes place in London or 
elsewhere in the country.
In preparation for the 2012 Olympic Games it is proposed, as 
far as available resources allow, that the NPIS will:
a Provide additional staffi ng over the period around the 
Olympics to support enhanced resilience 
b Develop appropriate mechanisms to allow temporary 
registered access to TOXBASE for appropriate Olympics 
associated healthcare providers
c Develop improved monitoring of unusual enquiry patterns 
on the NPIS databases UKPID and TOXBASE, to act as 
sentinels for mass or unusual chemical exposures 
d Update the clinical advice held on TOXBASE relating to the 
effects of known chemicals and products considered likely 
to be potential threats, including their effects on pregnant 
women and children
e Survey NHS laboratories and provide up-to-date advice and 
information on the local availability and use of relevant 
laboratory assays 
f Conduct a survey of NHS trusts to update NPIS information 
on local NHS hospital holdings of relevant antidotes. This 
should ensure up-to-date advice and information at the 
time of the Olympics on the local availability of such 
antidotes
g Consider adding specifi c data and functionality to TOXBASE 
to address the potential needs of the Olympics with 
respect to clinical toxidromes and complex searching.
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Staff of the NPIS are active in research relating to clinical 
toxicology and poisoning, as evidenced by the numbers of 
articles published in the medical literature listed in our annual 
reports (see Appendix B). This research is not a core function 
of the NPIS units but is important for increasing the evidence 
base for NPIS advice on poisons management. It is often 
performed during academic sessions held with universities 
and funded by external grants. Some examples of research 
performed over the last fi ve years involving NPIS staff are 
provided below.
7.1 Paracetamol 
Paracetamol is the most common medicine taken in overdose 
in the UK and the most common source of enquiries to 
the NPIS. 
In 1998 the UK health departments limited the availability 
of paracetamol by over-the-counter sale. Understanding 
the impact of these changes is important in planning future 
interventions aimed at reducing the risk of drugs available by 
this route. The NPIS unit in Edinburgh, working in collaboration 
with the Information and Statistics Division of the Scottish 
Health Department, has shown that the overall impact 
in Scotland was not what had been expected when the 
legislation was introduced. While there was an initial reduction 
both in hospital presentations and in deaths, after two years 
hospital admissions and mortality returned to the levels seen 
prior to legislation, and subsequently rose above them1.
In order to understand this change in more detail specifi c 
studies were carried out linking population deprivation and 
outcomes. This showed that the major impact of paracetamol-
induced morbidity and mortality was in deprived populations, 
principally in the cities, and that these populations had not 
benefi ted from the change in legislation2.
1  Bateman DN, Gorman DR, Bain M, Inglis JHC, House FR, Murphy D. 
Legislation restricting paracetamol sales and patterns of self-harm and 
death from paracetamol-containing preparations in Scotland. Br J Clin 
Pharmacol 2006: 62: 573–81.
2  Gorman DR, Bain M, Inglis JHC, Murphy D, Bateman DN. How 
has legislation restricting paracetamol pack size affected patterns of 
deprivation related inequalities in self-harm in Scotland? Public Health 
2007; 121: 45–50.
This work has important international implications since 
paracetamol poisoning is the major cause of drug-related 
morbidity and mortality worldwide. It suggests that a simple 
approach of limiting availability by restricting supply at the 
point of sale may not be fully effective. One of the diffi culties 
with the UK change is that it was not legally enforced and that 
many of the changes were in fact discretionary. It is also clear 
that patients can travel from one commercial outlet to another 
and collect large numbers of tablets with impunity.
Treatment of paracetamol poisoning involves using an 
intravenous antidote, acetylcysteine. This antidote is 
commonly associated with adverse effects such as vomiting, 
rash, wheeze, chest pain, and falls in blood pressure. These 
features suggest allergy but our work has shown that, although 
they are due to release of histamine in susceptible patients, 
this is not an allergic response3.
This research has confi rmed that patients who have previously 
had such adverse reactions can be treated without increased 
risk. In addition, understanding more of the adverse events 
allows a more targeted treatment to be administered to those 
patients who suffer adverse effects. 
It has been noted that patients who have lower blood 
concentrations of paracetamol are more likely to develop 
adverse effects to the antidote. These adverse effects mimic 
acute allergic reactions and are thought to involve histamine 
but are not thought to be due to an immunologically 
mediated mechanism. 
Work in Cardiff used a human mast cell culture to examine 
the effects of paracetamol and N-acetylcysteine, the 
antidote to paracetamol poisoning, on release of histamine 
from mast cells. This demonstrated that N-acetylcysteine 
causes an increased release of histamine from mast cells, 
but that paracetamol does not. Importantly, the addition of 
paracetamol and N-acetylcysteine to the cell culture resulted 
in a smaller release of histamine, mimicking the situation 
seen clinically. The human cells used do not express IgE 
receptors on their surface. As these receptors are necessary 
to produce classical anaphylactic reactions, this provides 
further evidence that these adverse effects are related to the 
3  Pakravan N, Waring WS, Sharma S, Ludlam C, Megson I, Bateman DN. 
Risk factors and mechanisms of anaphylactoid reactions to acetylcysteine 
in acetaminophen overdose. Clin Toxicol 2008; 46: 697–702.
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concentration of the antidote and not an aberrant immune 
response. The same effect was also observed in peripheral 
blood mononuclear cells taken from volunteers, suggesting 
that cells other than mast cells may be involved in these 
adverse reactions1.
Because of the risk of these adverse effects, it is not considered 
appropriate to give acetylcysteine to all patients with 
paracetamol overdose. Appropriate patients for treatment are 
identifi ed by measuring plasma paracetamol concentration 
and relating this to the time since overdose using a 
nomogram. While this approach is almost invariably effective, 
there are occasional reports of patients who develop toxicity 
at unexpectedly low plasma paracetamol concentrations. 
To investigate this further, research involving the NPIS units 
in Newcastle and Edinburgh was performed to quantify the 
numbers of paracetamol overdose patients with severe liver 
failure who had paracetamol concentrations below current 
thresholds. While some patients were identifi ed in liver units, 
these were very uncommon. As a result, change to national 
treatment advice has not been recommended2.
The adverse effects of acetylcysteine occur early during 
therapy when infusion rates and plasma concentrations are 
at their highest. The possibility that alteration to the infusion 
schedule, as well as the prophylactic use of antiemetics, might 
reduce the frequency of adverse effects will be investigated 
in a randomised clinical trial taking place in Edinburgh and 
Newcastle. This study, one of the fi rst studies in the UK in 
patients with acute drug overdose, has now received funding 
and ethical approval and will start recruiting patients in 2010. 
Further research in Edinburgh has focused on the identifi cation 
of new markers and drug targets that will improve the care 
of poisoned patients. The protein cyclophilin A has been 
identifi ed as a new mediator of organ injury in paracetamol 
poisoning and biomarker validation studies are now being 
performed in clinical samples. Research has also discovered 
in human urine and cerebrospinal fl uid a population of fat 
1  Coulson J, Thompson JP. Paracetamol (acetaminophen) attenuates 
in vitro mast cell and peripheral blood mononucleocyte cell histamine 
release induced by N-acetylcysteine. Clin Toxicol 2010; 48:111–14.
2  Beer C, Pakravan K, Hudson M, Smith LT, Simpson K, Bateman DN, 
Thomas SHL. Frequency of liver unit admission following paracetamol 
overdose when paracetamol concentrations are below current United 
Kingdom treatment thresholds. QJM 2007; 100: 93–6.
droplets (exosomes) that contain a range of proteins that 
change with organ damage. These exosomes represent a novel 
reservoir for further biomarker discovery3.
7.2 Co-proxamol
While studying the effects of the licence change on 
paracetamol poisoning it became clear that in Scotland many 
deaths occurred before patients reached hospital. This was 
unexpected as paracetamol usually causes death three to 
fi ve days after ingestion. Further work revealed that the effect 
was probably due to the ingestion of the combination product 
co-proxamol (paracetamol with dextropropoxyphene). Further 
studies in Edinburgh confi rmed dose-related abnormalities of 
the electrocardiogram which would predispose to ventricular 
arrhythmias and death4.
The evidence of risk in overdose and the lack of evidence 
that this painkiller was better than paracetamol alone led 
the UK licensing authority to withdraw co-proxamol from 
the market. NPIS research documented a rapid decline in 
mortality attributable to co-proxamol, subsequently confi rmed 
by research in England or Wales. The net result is a saving in 
approximately 200 deaths annually5.
7.3 Antidepressants
Over the past decade there has been a major change in the 
management of psychiatric illness with the introduction of 
a range of new, potentially less hazardous antidepressants 
and antipsychotics. Understanding the toxicity of these drugs 
in overdose is, however, important in order that physicians 
may be appropriately advised on the best choice for patients 
at high risk of suicide, and in order to manage acute 
poisoning effectively. 
3  Dear JW, Leelahavanichkul A, Aponte A, Hu X, Constant SL, Hewitt 
SM, Yuen PS, Star RA. Liver proteomics for therapeutic drug discovery: 
inhibition of the cyclophilin receptor CD147 attenuates sepsis-induced 
acute renal failure. Crit Care Med 2007; 35: 2319–29.
4  Afshari R, Maxwell SRJ, Dawson AH, Bateman DN. ECG abnormalities in 
co-proxamol (paracetamol/dextropropoxyphene) poisoning. J Toxicol Clin 
Toxicol 2005; 43: 255–9.
5  Sandilands EA, Bateman DN. Co-proxamol withdrawal has reduced 
suicide from drugs in Scotland. Br J Clin Pharmacol 2008; 66: 290–93.
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Studies in Edinburgh have shown a clear differential between 
the toxicity of a range of antidepressant drugs taken in 
overdose. By examining changes in the ECG and collecting 
data on the rates of convulsions in overdose, it has been 
possible to categorise drugs within individual therapeutic 
groups as being more or less hazardous. We were thus able 
to show that venlafaxine and citalopram were more toxic 
than other drugs in their class and intermediate in toxicity 
between traditional tricyclic antidepressants and safer SSRIs1. 
We were also able to show that mirtazapine was the safest 
antidepressant when taken in overdose2.
7.4 Antipsychotic Drugs
Staff in NPIS Newcastle have been involved in research into 
arrhythmias caused by drug treatment during therapeutic 
use and after overdose. This research has demonstrated 
electrocardiographic abnormalities (QT interval prolongation) 
to be much more common with thioridazine and droperidol 
than with other antipsychotic drugs and that these effects are 
associated with an increased risk of sudden death in patients 
receiving these drugs in normal doses. 
More recent research has studied the effects of genetic 
variations in liver metabolism on the cardiac effects of 
thioridazine. Although genetic variations affect the patterns 
of metabolites formed in users of thioridazine, the cardiac 
effects are similar because the metabolites have similar 
cardiac effects to the parent drug3,4. 
A further large-scale study is being performed comparing 
cardiac effects and other clinical outcomes between 
different antipsychotics, including the newer atypical agents, 
after overdose.
1  Kelly CA, Dhaun N, Laing EJ, Strachan FE, Good AM, Bateman DN. 
Comparative toxicity of citalopram and the newer antidepressants after 
overdose. J Toxicol Clin Toxicol 2004; 42: 67–71.
2  Waring WS, Good AM, Bateman DN. Lack of signifi cant toxicity after 
mirtazapine overdose: a fi ve-year review of cases admitted to a regional 
toxicology unit. Clin Toxicol 2007; 45: 45–50.
3  Salih ISM, Thanacoody RHK, McKay GA, Thomas SHL. Comparison of 
the effects of thioridazine and mesoridazine on the QT interval in healthy 
adults after single oral doses. Clin Pharmacol Ther 2007; 82: 548–54. 
4 Thanacoody RHK, Daly AK, Reilly JG, Ferrier IN, Thomas SHL. Factors 
affecting drug concentrations and QT interval during thioridazine therapy. 
Clin Pharmacol Ther 2007; 82: 555–65.
7.5 Heavy Metal Poisoning
NPIS Birmingham, in association with the West Midlands 
Poisons Unit at City Hospital, has been involved in the clinical 
evaluation of antidotes for heavy metal poisoning. Specifi cally, 
the units have published in 2009 the largest case series of 
patients treated with DMSA (dimercaptosuccinic acid) in adult 
lead poisoning which had comprehensive data on blood 
and urine lead concentrations5. This was accompanied by 
two detailed reviews6,7.
7.6 Pesticides
In addition to acute poisonings, staff contributing to the NPIS 
have interests in both acute and longer-term environmental 
and occupational exposures to chemicals, including pesticides 
and veterinary medicines.
Studies in Edinburgh have focused on pesticide toxicity in Asia, 
where high rates of death are caused by intentional pesticide 
overdose. This work has included large clinical trials of 
activated charcoal and specifi c antidotes which have informed 
the management of poisoning worldwide8,9. In addition, 
public health programmes have been developed and shown to 
successfully reduce the number of deaths by removing more 
toxic pesticides from the marketplace10. 
5  Bradberry S, Sheehan T, Vale A. Use of oral dimercaptosuccinic acid 
(succimer; DMSA) in adult patients with inorganic lead poisoning. QJM 
2009; 102: 721–32.
6  Bradberry S, Vale A. Dimercaptosuccinic acid (succimer; DMSA) in 
inorganic lead poisoning. Clin Toxicol 2009; 47: 617–31.
7  Bradberry SM, Vale JA. A comparison of sodium calcium edetate 
(edetate calcium disodium) and succimer (DMSA) in the treatment of 
inorganic lead poisoning. Clin Toxicol 2009; 47: 841–58.
8  Eddleston M, Juszczak E, Buckley NA, Senarathna L, Mohamed F, 
Dissanayake W, Hittarage A, Azher S, Jeganathan K, Jayamanne S, Sheriff 
MR, Warrell DA; Ox-Col Poisoning Study collaborators. Multiple-dose 
activated charcoal in acute self-poisoning: a randomised controlled trial. 
Lancet 2008; 16: 371(9612): 579–87. 
9  Eddleston M, Eyer P, Worek F, Juszczak E, Alder N, Mohamed 
F, Senarathna L, Hittarage A, Azher S, Jeganathan K, Jayamanne S, 
von Meyer L, Dawson AH, Sheriff MH, Buckley NA. Pralidoxime in acute 
organophosphorus insecticide poisoning – a randomised controlled trial. 
PLoS Med 2009; 30: 6(6).
10  Gunnell D, Fernando R, Hewagama M, Priyangika WD, Konradsen F, 
Eddleston M. The impact of pesticide regulations on suicide in Sri Lanka. 
Int J Epidemiol 2007; 36: 1235–42.
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In the UK concern has been raised over the possible toxicity 
of products used to control parasites on sheep, and indeed 
for a while some of these products were withdrawn from the 
market. Staff from the Cardiff unit, together with research 
colleagues from London and Manchester, have undertaken the 
largest study of its kind investigating the potential effect on 
health of using sheep dips.
The aim of the study was to determine the nature and 
frequency of signs of ill-health amongst farmers treating 
sheep, and to determine whether those farmers who 
developed fl u-like symptoms differed in their exposure to 
organophosphorus (OP) compounds, endotoxins and infectious 
agents when compared with other farmers operating at the 
same time who remained free of symptoms. 
A total of 781 farmers were recruited and interviewed for 
the study. Although 7% of farmers felt ill on the day prior to 
dipping, this fell to 3% during the fi rst three days after dipping 
and even lower later in the week. Symptoms were less likely to 
be reported by farmers holding a certifi cate of competence. 
Few farmers (less than 2%) were identifi ed as having 
‘dippers’ fl u’. The increased symptom reporting found during 
the study was unlikely to have resulted from any of the 
exposures examined and further work would be required to 
identify the cause of the increased symptom reporting1.
7.7 Drug Exposure in Pregnancy
UKTIS has been collecting data on pregnancy outcomes 
following exposure to medicines and chemicals in pregnancy 
for many years and publishes information relating to individual 
agents when the data are suffi cient.
A/H1N1v infl uenza in pregnancy
During 2009/10, the emergence of the pandemic of A/H1N1v 
infl uenza (‘swine fl u’) focused research efforts on establishing 
the maternal and fetal effects of the infection, the antiviral 
drugs used as treatment and prophylaxis, and the safety of the 
new vaccines used for prevention.
1  Povey AC, Rees HG, Thompson JP, Karaliedde L. Prospective cohort 
study of sheep dip exposure and ‘dipper’s fl u’. RR775. HSE Books, 2010.
A collaborative venture with the UK Obstetric Surveillance 
System (UKOSS) was initially commissioned for six months by 
the National Institute for Health Research (NIHR) as high priority 
expedited research to collect prospective observational data 
on pregnant women exposed to swine fl u and/or antiviral 
medication, managed in both primary (UKTIS) and secondary 
(UKOSS) care. Monthly review of emerging data from this 
study was provided to the NIHR to inform guidance on the 
management of A/H1N1v infection in pregnancy during 
the 2009 pandemic such that outcomes for women and 
infants were optimised during this period. By comparing 
pregnant women with infl uenza symptoms with a control 
group of uninfected women, a two-fold increase in risk of GP 
presentation has been shown in women with asthma.
Additional funding has subsequently been provided to the 
Newcastle upon Tyne Hospitals NHS Foundation Trust (NUTH) 
by the swine fl u vaccine manufacturers, GSK and Baxter, to 
include women offered swine fl u vaccination in pregnancy in 
the UKTIS arm of the study. The study is still recruiting, with 
over 2700 women reported to UKTIS to date. It is recognised 
globally that there is a pressing need for good data on 
maternal and longer term fetal outcomes following infl uenza, 
antiviral or vaccine exposure in pregnancy, not only in view 
of the likelihood that A/H1N1v will remain the dominant 
circulating infl uenza strain during the winter of 2010, but 
also given the likelihood of other, potentially more virulent 
infl uenza outbreaks in the future.
The study is currently due to run until April 2011, at which 
stage data on pregnancy outcome and infant development 
and health at the age of six months will be available for 
analysis. Interim results of this research have been published2.
Pharmacoepidemiological research on 
outcomes of therapeutics (PROTECT)
UKTIS is one of 20 centres led by the European Medicines 
Agency involved in a European-wide pharmacovigilance 
research project. The consortium will develop and test 
2  Yates L, Pierce M, Stephens S, Mill AC, Spark P, Kurinczuk JJ, 
Brocklehurst P, Thomas SHL, Knight M. Infl uenza A/H1N1v in pregnancy: 
an investigation of the characteristics and management of affected 
women and the relationship to pregnancy outcomes for mother and 
infant. Health Technology Assessment 2010; 14: 109–82.
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methods of proactive monitoring of drug safety using 
expertise from UKTIS and other centres in the EU. UKTIS 
is involved in a pilot project to collect data directly from 
pregnant patients to improve the way in which adverse drug 
reporting data are collected. 
Epigenetic signatures of teratogenesis in the 
human embryo
UKTIS has secured NIHR Flexibility and Sustainability Funding to 
produce pilot data towards a larger project grant application. 
This will involve the collection of baseline data on ‘normal’ 
methylation patterns in the developing human fetus at various 
time points during pregnancy. Further funding to compare 
these data with methylation signals in fetuses exposed to 
drugs or other environmental chemicals will be sought, with 
the aim of identifying teratogenic signatures resulting from 
such exposures, offering the potential of improved insight into 
teratogenic mechanisms, and better methods for predicting 
the effects of drugs and chemicals on the fetus.
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This review of the NPIS for 2009/10 confi rms that all 
components of the service continue to work well as an 
integrated national network. The number of enquiries from all 
sources appears to be plateauing. The successful collaborative 
working of the NPIS units is illustrated by the increase in 
entries on the TOXBASE database edited, reviewed and written 
this year. In addition, paediatric consultants now routinely 
participate in the review of relevant TOXBASE entries. 
While there has been a welcome expansion in the number of 
consultants who are now available to support the out-of-hours 
service, all the cover is provided by eight full-time-equivalent 
consultants working part-time for the NPIS, which serves the 
whole of the UK on a 24-hour-a-day basis – a most cost-
effective service model.
Stakeholder feedback demonstrates a continuous high level 
of user satisfaction with TOXBASE, the telephone information 
services provided by the NPIS and UKTIS, and with the advice 
provided by NPIS consultants. Feedback from TOXBASE users 
has also enabled specifi c improvements in the database to 
be made. 
This year’s report illustrates some of the public health areas 
that NPIS data have the potential to support. There was 
an increase in the numbers of enquiries that involve new 
cathinone drugs of misuse. New agents continue to present – 
the NPIS monitors these and TOXBASE entries are developed to 
support frontline NHS staff.
2009/10 marked the fi fth year of networked arrangements 
for the NPIS units, following establishment of a common NPIS 
rota in 2005. This has increased the effi ciency of the service 
by more collaborative working between units and improved 
the consistency of its advice. The clinical governance review 
in the early years set a useful strategic direction to underpin 
the development of common processes and operating 
procedures. Continued professional development programmes 
are now established for all staff.
Many enquiries about children relate to exposures at home 
to household products. A detailed project was undertaken 
and key fi ndings are included in this report. A common 
exposure was to ‘liquitabs’. These were associated with 
acute eye symptoms and unusually some cases of sedation 
after ingestion.
The phased withdrawal of co-proxamol has allowed the NPIS 
to assess the effect of this action in reducing poisons enquiries 
over time. These NPIS data are more rapidly available than 
other public health data, as they are collected and can be 
analysed in near real time.
An increased risk of adverse fetal outcomes following 
maternal exposures or overdose cannot be excluded for 
many substances, as available data on pregnancy outcome 
are limited. UKTIS continues to collect these data to make 
available to healthcare professionals to help guide their 
clinical decisions.
8 Conclusions
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 Recommendations and Outcomes for 
2009/10
1 To review and further develop stakeholder feedback and 
quality assurance on all aspects of the NPIS 
Outcome  Review conducted and quality assurance 
systems of all aspects of the NPIS and UKTIS confi rmed as 
‘fi t for purpose’, including user feedback on TOXBASE.
2 To establish a forum with partner agencies to consider 
what further steps could be taken to prevent poisoning, 
including developing a framework for the provision of such 
advice for the general public.
Outcome  Deferred due to fi nancial constraints and 
funding uncertainties.
3 To continue to develop ‘short advice boxes’ on the most 
common and potentially most toxic ingestions as part of 
the ongoing TOXBASE editing process in the absence of 
specifi c funding to accelerate this activity
Outcome  Achieved and ongoing work programme 
continued
4 To increase the profi le of UKTIS amongst clinical user 
groups
Outcome  Profi le increased with key user groups by 
relaunch of UKTIS and publicity associated with the 
A/H1N1v infl uenza pandemic. Further developments 
planned for 2010/11 
5 To plan a second meeting with major funding bodies 
and stakeholders to review the current NPIS provision and 
establish their priorities for the service
Outcome  Meeting deferred due to recent constraints
Recommendations for 2010/11
1 To work to ensure that future NPIS and UKTIS 
commissioning arrangements are appropriate and 
consistent with the evolving policy for public health
2 To ensure arrangements are appropriate to enable the NPIS 
and UKTIS to provide optimal support to the London 2012 
Olympic Games
9 Recommendations
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NPIS Affi liated Consultants
NPIS Birmingham
Dr S M Bradberry BSc MD MRCP
Assistant Director, NPIS Birmingham and West Midlands Poisons Unit, 
City Hospital
Professor J A Vale MD FRCP FRCPE FRCPG FFOM FAACT FBTS Hon FRCPSG
Director, NPIS Birmingham and West Midlands Poisons Unit, and 
Consultant Clinical Pharmacologist, City Hospital; School of Biosciences 
and College of Medical and Dental Sciences, University of Birmingham
NPIS Cardiff
Dr C V Krishna MBBS MD FRCP(Lon) DipTox DipTher
Consultant Physician, Clinical Pharmacologist and Toxicologist, Cardiff and 
Vale University Health Board, and Honorary Clinical Senior Lecturer, Cardiff 
University
Professor P A Routledge OBE MD FRCP FRCPE FBTS
Professor of Clinical Pharmacology and Head of Pharmacology, Radiology 
and Oncology, Cardiff University
Dr A Thomas MBChB
Senior Lecturer in Clinical Pharmacology and Honorary Consultant 
Physician, Cardiff University
Dr J P Thompson FRCP FBTS
Director, NPIS Cardiff, and Senior Lecturer in Clinical Pharmacology, Wales 
College of Medicine, Cardiff University
NPIS Edinburgh
Professor D N Bateman BSc MD FRCP FRCPE FBPharmacolS FBTS FAACT
Director, NPIS Edinburgh, and Professor of Clinical Toxicology, University of 
Edinburgh, and Consultant Physician, Royal Infi rmary of Edinburgh
Dr J Dear PhD MRCP
Consultant Clinical Toxicologist and Physician, Royal Infi rmary of Edinburgh
Dr M Eddleston MA PhD MRCP
Scottish Senior Clinical Research Fellow, University of Edinburgh, and 
Honorary Consultant Physician, Royal Infi rmary of Edinburgh
Dr A Veiraiah MB BS MRCP
Consultant Clinical Toxicologist and Physician, Royal Infi rmary of Edinburgh
NPIS Newcastle (including UKTIS)
Dr H K R Thanacoody MD FRCPE
Consultant Physician and Clinical Toxicologist, Royal Victoria Infi rmary, and 
Honorary Senior Clinical Lecturer, Institute of Cellular Medicine, Newcastle 
University
Professor S H L Thomas BSc MD FRCP FRCPE
Director, NPIS Newcastle and UKTIS, and Consultant Physician, Newcastle 
Hospitals NHS Foundation Trust, and Professor of Clinical Pharmacology 
and Therapeutics, Newcastle University
Dr L Yates MBChB DRCOG MRCPCH PhD
Head of Teratology, UKTIS, and Consultant in Clinical Genetics
Consultants also providing on-call support for 
the NPIS
Dr P I Dargan MBBS FRCPE FACMT
Consultant Physician and Clinical Toxicologist and Clinical Director, Guy’s 
and St Thomas’ NHS Foundation Trust and King’s Health Partners, London
Dr W S Waring BMedSci MB PhD FRCPE
Consultant Physician in Acute Medicine and Toxicology, York Hospital, and 
Honorary Senior Lecturer in Medicine, Hull York Medical School, York
Dr D M Wood BSc(Hons) MBChB(Hons) MRCP MD
Consultant Physician and Clinical Toxicologist, Guy’s and St Thomas’ NHS 
Foundation Trust and King’s Health Partners, London
Consultants providing specialist paediatric 
support for the NPIS
Dr T Beattie MB MSc FRSCEd(A&E) FCEM FRCPE FFSEM FFSEM(RCPSI) DCH
Consultant in Paediatric Emergency Medicine, Royal Hospital for Sick 
Children, Edinburgh
Dr D Bloomfi eld MB BS MRCPCH
Consultant in Paediatric Emergency Medicine, Royal Hospital for Sick 
Children, Edinburgh
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ADVISORY COMMITTEES
Chairman: Ministry of Defence Research Ethics Committee
Member: MHRA Clinical Trials Collaboration Group
Consultant: Dstl Porton Down
Member: Expert Advisory Group on Management of Casualties Caused by 
Chemical Terrorism (Blain II)
Member: National Patient Safety Board: Medication Safety Board
UK ACADEMIC ACTIVITIES
Joint Course Organiser: MSc (Toxicology), University of Birmingham
Examiner: MRCP Part 2 Clinical Examination (PACES)
External Examiner: Cardiff University
Examiner: Faculty of Occupational Medicine
Member: British Pharmacological Society
Fellow: British Toxicology Society
Member: Society of Occupational Medicine
Fellow: Faculty of Occupational Medicine
NPIS Cardiff
Dr C V Krishna
ADVISORY COMMITTEES
Chairman: All Wales Specialist Training Committee in Clinical 
Pharmacology and Therapeutics
Member: New Medicines Group, All Wales Medicines Strategy Committee
UK NHS COMMITTEES 
Senior Medical Offi cer: Yellow Card Centre (Wales)
UK ACADEMIC ACTIVITIES
Deputy Course Coordinator: Certifi cate/Diploma/MSc in Medical 
Toxicology, Cardiff University
Member: Steering Committee, Diploma in Therapeutics, Cardiff University
Member: Steering Committee, Diploma/MSc in Therapeutics, Cardiff 
University
Professor P A Routledge
INTERNATIONAL ACTIVITIES
Associate Director: World Health Organization Clearing House for 
Chemical Incidents, Cardiff, Wales
INTERNATIONAL JOURNALS
Editorial Board Member: Adverse Reactions and Acute Poisoning Reviews
Editorial Board Member: Adverse Drug Reactions Bulletin
ADVISORY COMMITTEES
Chairman: UK Herbal Medicines Advisory Committee
Chairman: All-Wales Medicines Strategy Group
Consultant Advisor in Toxicology to the Chief Medical Offi cer (Wales)
National and International Appointments 
of NPIS Affi liated Staff
NPIS staff have a role in supporting many important aspects of 
toxicology, both nationally and internationally. These include 
advisory roles to international and national bodies, including 
government, as well as academic activities. The range of their 
roles presented below provides a fl avour of these activities and 
indicates the wider ‘added value’ of the NPIS.
NPIS Birmingham
Dr S M Bradberry
INTERNATIONAL ACTIVITIES
Board Member: European Association of Poison Centres and Clinical 
Toxicologists
Scientifi c Committee Member: European Association of Poison Centres 
and Clinical Toxicologists
INTERNATIONAL SOCIETIES
Member: European Association of Poison Centres and Clinical Toxicologists
Member: American Academy of Clinical Toxicology
INTERNATIONAL JOURNALS
Senior Editorial Board Member: Clinical Toxicology
ADVISORY COMMITTEES
Member: Health and Safety Executive Pesticide Incident Appraisal Panel
UK ACADEMIC ACTIVITIES
Honorary Lecturer: School of Biosciences, University of Birmingham
Joint Course Organiser: MSc (Toxicology), University of Birmingham
Educational Supervisor: Sandwell and West Birmingham Hospitals NHS 
Trust
Member: British Toxicology Society
Member: Society of Occupational Medicine
Professor J A Vale
INTERNATIONAL ACTIVITIES
Member: Advisory Board Hong Kong Poisons Centre
INTERNATIONAL SOCIETIES
Fellow: American Academy of Clinical Toxicology
Member: European Association of Poison Centres and Clinical Toxicologists
Member: Society of Toxicology
American Academy of Clinical Toxicology: Lifetime Achievement Award 
Lecturer
INTERNATIONAL JOURNALS
Reviews Editor: Clinical Toxicology
Editorial Board Chairman: Medicine
Editorial Board Member: Drugs
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UK ACADEMIC ACTIVITIES
President Elect: British Pharmacological Society
External Advisory Board Member: Liverpool School of Biomedical Sciences
Chairman: All Wales Specialist Training Committee in Clinical 
Pharmacology
Course Director: Postgraduate Diploma/MSc Programmes in Medical 
Toxicology, Therapeutics and Occupational Health, Cardiff University
Faculty Lead: Medicines Management, 1000 Lives Pus Campaign, Wales
Honorary Secretary: Clinical Pharmacology Colloquium
Dr A Thomas
ADVISORY COMMITTEES
Member: New Medicines Group, All Wales Medicines Strategy Committee 
Member: All-Wales Specialist Training Committee in Clinical Pharmacology 
UK NHS COMMITTEES 
Deputy Director: Yellow Card Centre Wales
UK ACADEMIC ACTIVITIES
Member: Steering Committee, Diploma/MSc in Medical Toxicology, Cardiff 
University
Member: Steering Committee, Diploma in Therapeutics, Cardiff University  
Dr J P Thompson
INTERNATIONAL ACTIVITIES
Member: Advisory Board Hong Kong Poisons Centre
INTERNATIONAL SOCIETIES
Chair: Human Toxicology Section British Toxicology Society
Member: Clinical Section Committee, British Pharmacological Society
Member: American Academy of Clinical Toxicology
Member: European Association of Poison Centres and Clinical Toxicologists
ADVISORY COMMITTEES
Member: Appraisal Panel for Suspected Adverse Reactions to Veterinary 
Medicines
Member: Expert Advisory Group on Management of Casualties Caused by 
Chemical Terrorism (Blain II)
Member: New Medicines Group, All Wales Medicines Strategy Committee
Senior Medical Offi cer: Yellow Card Centre (Wales)
Member: All-Wales Specialist Training Committee in Clinical Pharmacology
UK ACADEMIC ACTIVITIES
Member: Specialist Question Writing Group for Clinical Pharmacology and 
Therapeutics of the Royal College of Physicians
Course Coordinator: Certifi cate/Diploma/MSc in Medical Toxicology, 
Cardiff University
Member: Steering Committee, Diploma in Therapeutics, Cardiff University
Member: Steering Committee, MSc in Occupational Health, Policy and 
Practice, Cardiff University
NPIS Edinburgh
Professor D N Bateman
INTERNATIONAL ACTIVITIES
Advisor: World Health Organization/International Programme on Chemical 
Safety
INTERNATIONAL SOCIETIES
Member: European Association of Poisons Centres and Clinical 
Toxicologists
Scientifi c Committee Member: European Association of Poisons Centres 
and Clinical Toxicologists
Fellow: American Academy of Clinical Toxicology
INTERNATIONAL JOURNALS
Editor in Chief: Clinical Toxicology
ADVISORY COMMITTEES
Member: Pharmacovigilance Expert Advisory Group, Medicines and 
Healthcare products Regulatory Agency
Member: Expert Advisory Group on Management of Casualties Caused by 
Chemical Terrorism (Blain II)
Member: Pesticides Adverse Health Effects Surveillance Working Group of 
the Advisory Committee on Pesticides
UK NHS COMMITTEES
Board Member: Yellow Card Centre (Scotland) 
Expert Toxicology Advisor: Scottish Government
UK ACADEMIC ACTIVITIES
Training Programme Director for Scotland’s Clinical Pharmacology and 
Therapeutics Programme (from Aug 2009)
Member of Executive: British Toxicological Society (until April 2010)
Member: British Pharmacology Society
Board Member: Joint Royal Colleges MRCP (Part 1) Examining Board (until 
Nov 2009)
Board Member: Joint Royal Colleges MRCP (Part 1) Standard Setting Group 
(until Nov 2009)
Dr J Dear
INTERNATIONAL SOCIETIES
Member: European Association of Poison Centres and Clinical Toxicologists 
UK NHS COMMITTEES
Member: Lothian Formulary Committee
UK ACADEMIC ACTIVITIES
Reviewer: Clinical Toxicology, European Journal of Clinical Pharmacology, 
British Journal of Pharmacology
Tutor: MSc in Translational Medicine, Edinburgh University
External Examiner: MRes in Translational Medicine, Newcastle University
Member: British Pharmacological Society
Member: Clinical Pharmacology Specialty Question Group, MRCP(UK)
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Dr M Eddleston
INTERNATIONAL ACTIVITIES
Advisor: World Health Organization/Department of Mental Health
INTERNATIONAL SOCIETIES
Board Member: Asia Pacifi c Association of Medical Toxicology
Member: European Association of Poison Centres and Clinical Toxicologists 
UK ACADEMIC ACTIVITIES
Member: Association of Physicians of Great Britain and Ireland
Member: British Pharmacology Society
Member: British Toxicological Society
Member: Royal Society of Tropical Medicine and Hygiene
Mrs A M Good
INTERNATIONAL SOCIETIES
General Secretary: European Association of Poisons Centres and Clinical 
Toxicologists
Dr A Veiraiah
INTERNATIONAL SOCIETIES
Member: European Association of Poison Centres and Clinical Toxicologists 
NPIS Newcastle
Dr H K R Thanacoody
INTERNATIONAL SOCIETIES
Member: European Association of Poison Centres and Clinical Toxicologists 
ADVISORY COMMITTEES
Member: Independent Scientifi c Advisory Committee, Medicines and 
Healthcare products Regulatory Agency
UK ACADEMIC ACTIVITIES
Member: Question Writing Group: Joint Royal Colleges MRCP (Part 1) 
Examining Board
Module Leader: Diploma in Therapeutics and MRes Experimental Medicine 
and Therapeutics, Newcastle University
Professor S H L Thomas
INTERNATIONAL SOCIETIES
President-elect: European Association of Poisons Centres and Clinical 
Toxicologists
Expert Panel Member: European Medicines Agency
INTERNATIONAL JOURNALS
Senior Editorial Board Member: Clinical Toxicology
International Editorial Board Member: British Journal of Clinical 
Pharmacology
ADVISORY COMMITTEES
Member: Commission for Human Medicines
Member: Technical Committee, Advisory Council on the Misuse of Drugs
Member: Expert Advisory Group on Management of Casualties Caused by 
Chemical Terrorism (Blain II)
Member: Ministry of Defence Advisory Committee on Military Medicine
Member: Ministry of Defence Research Ethics Committee
UK NHS COMMITTEES
Director: Yellow Card Centre Northern and Yorkshire
Medical Director: Regional Drug and Therapeutics Centre, Newcastle
UK ACADEMIC ACTIVITIES
Chair: Specialist Training Committee, Clinical Pharmacology and 
Therapeutics, Northern Deanery
Degree Programme Director: Certifi cate/Diploma in Therapeutics, 
Newcastle University
Consultants also providing on-call support for 
the NPIS
Dr P I Dargan
INTERNATIONAL ACTIVITIES
Adviser: World Health Organization/International Programme on Chemical 
Safety
Adviser: US Food and Drug Administration (FDA): attended and presented 
at an FDA Advisory Committee June 2009
Adviser: European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA)
INTERNATIONAL SOCIETIES
Member: International Advisory Board of the Indian Society of Toxicology
Vice Chairman: American College of Medical Toxicology (ACMT) 
International Committee. 
Scientifi c Committee Member: European Association of Poisons Centres 
and Clinical Toxicologists
INTERNATIONAL JOURNALS
Editorial Board Member: Quarterly Journal of Medicine 
Editorial Board Member: Case Reports in Medicine
ADVISORY COMMITTEES
Member: London Ambulance Service Clinical Audit and Research Steering 
Group
Co-chair: College of Emergency Medicine Antidote Guidelines Group
Adviser: Home Offi ce Advisory Council on the Misuse of Drugs 
Adviser: Department of Health UK Focal Point on Drugs 
Expert Advisory Panel: Medicines and Healthcare products Regulatory 
Agency Steering Group: National Programme for Substance Abuse Deaths
UK ACADEMIC ACTIVITIES
Member: King’s College London Phase 5 Exam Board
Examiner: King’s College London MPharm
Examiner: MRCP Part 2 Clinical Examination (PACES)
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Dr W S Waring
INTERNATIONAL JOURNALS
Associate Editor: Therapeutic Advances in Drug Safety 
Editorial Advisory Board member: Recent Patents on Cardiovascular Drug 
Discovery
Editorial Board Member: European Journal of Clinical Pharmacology 
Editorial Board Member: Expert Review of Clinical Pharmacology 
ADVISORY COMMITTEES
Member: Independent Review Panel for Borderline Products (MHRA)
Member: Independent Review Panel for Advertising (MHRA) 
Member: Advisory Committee on Pesticides (Defra) 
Member: Medical Toxicology Panel (Defra) 
UK ACADEMIC ACTIVITIES
Educational Lead: National Poisons Information Service CPD programme
Examiner: MRCP Part 2 Clinical Examination (PACES)
External Examiner: Certifi cate and Diploma in Clinical Pharmacology, 
Newcastle University
Member: Specialist Advisory Committee in Toxicology (RCPPath)
Member: Clinical Section Committee, British Pharmacology Society
Dr D M Wood
INTERNATIONAL ACTIVITIES
Adviser: European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA)
INTERNATIONAL SOCIETIES
European Regional Director: American College of Medical Toxicology 
(ACMT) International Committee. 
Abstract Reviewer: European Association of Poisons Control Centres and 
Clinical Toxicologists Annual Meeting
ADVISORY COMMITTEES
Adviser: Home Offi ce Advisory Council on the Misuse of Drugs 
Adviser: Department of Health UK Focal Point on Drugs 
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Over 110 contributions to the scientifi c literature were 
published in 2009/10 by staff working in association with 
the NPIS.
Peer-reviewed Papers
Bell CL, Watson B, Waring WS. Acute psychosis caused by co-amoxiclav. 
Praxis 2009; 98: 765–6.
Bishop CR, Dargan PI, Greene SL, Garnham F, Wood DM. Emergency 
Department presentations with suspected Acute Coronary Syndrome – 
frequency of self-reported cocaine use and its associated clinical features. 
Eur J Emerg Med 2010; 17: 164–6.
Bradberry SM, Sheehan TMT, Barraclough CR, Vale JA. DMPS can reverse 
the features of severe mercury vapor-induced neurological damage. Clin 
Toxicol 2009; 47: 894–8.
Bradberry S, Sheehan T, Vale A. Use of oral dimercaptosuccinic acid 
(succimer; DMSA) in adult patients with inorganic lead poisoning. QJM 
2009; 102: 721–32.
Bradberry S, Vale A. Dimercaptosuccinic acid (succimer; DMSA) in 
inorganic lead poisoning. Clin Toxicol 2009; 47: 617–31.
Bradberry SM, Vale JA. A comparison of sodium calcium edetate (edetate 
calcium disodium) and succimer (DMSA) in the treatment of inorganic 
lead poisoning. Clin Toxicol 2009; 47: 841–58.
Campbell G, Leitch D, Lewington AJP, Dargan PI, Baker RJ. Minimal change 
nephrotic syndrome due to occupational mercury vapor inhalation. Clin 
Nephrol 2009; 72: 216–19. 
Coulson J, Thompson JP. Paracetamol (acetaminophen) attenuates in vitro 
mast cell and peripheral blood mononucleocyte cell histamine release 
induced by N-acetylcysteine. Clin Toxicol 2010; 48: 111–14. 
Dargan PI, Button JS, Davies S, Ramsey J, George S, Holt D, Wood DM. First 
reported UK fatality due to gamma-butyrolactone (GBL). J Roy Soc Med 
2009; 102: 546–7.
Doak MW, Nixon AC, Lupton DJ, Waring WS. Self-poisoning in older adults: 
patterns of drug ingestion and clinical outcomes. Age Ageing 2009; 38: 
407–11.
Eddleston M, Eyer P, Worek F, Juzsczak, Alder N, Mohamed F, Senarathna 
L, Hittarage A, Azher S, Jeganathan K, Jayamanne S, von Meyer L, Dawson 
AH, Sheriff MHR, Buckley NA. Pralidoxime in acute organophosphorus 
insecticide poisoning – a randomised controlled trial. PLoS Med 2009, 6: 
e1000104.
Eddleston M, Gunnell D, von Meyer L, Eyer P. Relationship between 
blood alcohol concentration on admission and outcome in dimethoate 
organophosphorus self-poisoning. Br J Clin Pharmacol 2009; 68: 916–19.
Eddleston M, Worek F, Eyer P, Thiermann H, von Meyer L, Jeganathan 
K, Sheriff MHR, Dawson AH, Buckley NA. Poisoning with the S-alkyl 
organophosphorus insecticides profenofos and prothiofos. QJM 2009; 
102: 785–92.
Eyer F, Roberts DM, Buckley NA, Eddleston M, Thiermann H, Worek F, Eyer 
P. Extreme variability in the formation of chlorpyrifos oxon in patients 
poisoned by chlorpyrifos. Biochem Pharmacol 2009; 78: 531–7.
Ferguson LP, Dargan PI, Hood JL, Tibby SM. Life-threatening organ failure 
following lamotrigine therapy. Pediatr Neurol 2009; 40: 392–4. 
Gratus C, Damery S, Wilson S, Warmington S, Routledge P, Grieve R, Steven 
N, Jones J, Greenfi eld S. The use of herbal medicines by people with 
cancer in the UK: a systematic review of the literature. QJM 2009; 102: 
831–42.
Hill S, Thomas SHL. What’s new in… Toxicity of drugs of abuse? Medicine 
2009; 37: 621–6.
John H, Eddleston M, Clutton RE, Worek F, Thiermann H. Simultaneous 
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